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Tumor cells are characterized by intrinsic proteotoxic stress and the accumulation of 
mutated proteins. Therefore, malignant cells depend on the activity of heat shock protein 90 
(HSP90) much more than normal cells to maintain a functionally intact proteome. Thus, the 
inhibition of HSP90 by small molecules is currently being evaluated as a new approach to 
cancer therapy. One of the most promising drugs of this class is ganetespib, which is 
currently in intensive clinical trials.  
We analyzed the susceptibility of colorectal cancer (CRC) cell lines to ganetespib and 
recorded large differences in the cell line-specific drug concentrations required for 50% 
growth inhibition (IC50). Two groups of cancer cells became apparent; ganetespib-sensitive 
and -resistant cell lines with a difference in IC50 values up to 70–fold (36 – 2,500 nM). 
Therefore, the aim of this study was to elucidate the molecular determinants that govern the 
response of CRC cells to ganetespib treatment.  
A statistical correlation of the IC50 values of CRC cell lines with their transcriptomes 
revealed that the expression of UDP-glucuronosyltransferase 1A (UGT1A) correlates 
strongly with resistance to ganetespib. UGT1A is involved in the metabolism of a variety of 
drugs, and it has been previously reported that high expression levels of this enzyme in 
cancer cells are responsible for the resistance to some established chemotherapeutic drugs. 
Knockdown of UGT1A in ganetespib-resistant cells and overexpression of UGT1A in 
ganetespib-sensitive cells confirmed the causal connection of increased ganetespib tolerance 
to the expression of UGT1A. The protective effect of UGT1A was also observed by 
immunoblot analysis of HSP90 clients, as they were not degraded in sensitive cell lines 
despite the presence of ganetespib when UGT1A was overexpressed.  
A similar resistance in cells with increased UGT1A expression was also observed for 
another, structurally related HSP90 inhibitor, NVP-AUY922. However, HSP90 inhibitors 
from other classes do not seem to be subject to glucuronidation-induced resistance 
mechanisms. We hypothesize that glucuronidation by UGT1A takes place at the resorcinol 
moiety of ganetespib and NVP-AUY922. The metabolites of this glucuronidation process, the 
glucuronides of ganetespib and NVP-AUY922, were detected by mass spectrometry in a 
collaborating laboratory to support this hypothesis. 
In summary, we show that the biological activities of ganetespib and NVP-AUY922, 




CRC cell lines. Notably, the UGT1A expression levels of primary CRC tumor samples have 
been found to be in the same range as in the CRC cell lines. Therefore, the occurrence of 
resistance to ganetespib and NVP-AUY922 in clinical applications is a conceivable scenario. 
We suggest that the expression of UGT1A can be used as a drug-related biomarker in cancer 
to ensure the activity of resorcinolic HSP90 inhibitors. These findings are of pivotal 










   Introduction 1.
 
 Global Perspective on Cancer Treatment  1.1
Malignant neoplasms, commonly referred to as cancer, represents the second most 
common cause of death worldwide and the leading cause of death in developed countries.
[1]
 
With the increasing life expectancy in developed and developing countries, as well as the 
continuing adaption of Western life style in emerging parts of the world, the global cancer 
incidence will rise significantly in the decades to come.
[2]
 Therefore, it becomes increasingly 
important to find new cancer therapies.  
Despite the advances that have been made in cancer research so far, there is still need 
for improvement of the efficacy and specificity of cancer therapeutics. Most of the drugs used 
today are either chemotherapeutics that cause DNA damage or drugs that inhibit signaling 
intermediates involved in cell growth. The major drawbacks of these established cancer drugs 
is the unspecific DNA-damaging character of chemotherapeutics that can give rise to 
secondary malignancies and the very frequent development of drug resistance in cells treated 
with drugs that target signaling pathways.
[3]
 The development of drug resistance by some 
tumors is one of the main obstacles researchers need to approach in the future.
[4]
 Promising 
approaches are the combination of multiple drugs or treatment with drugs that target cellular 
machineries that are essential for tumor growth, like the Hsp90 machinery (see chapters 1.3, 




 Colorectal Cancer 1.2
Colorectal cancer (CRC) is the second most frequent type of malignant tumors in men 
and in women in Germany, and every seventh malignant neoplasia develops in the colon or 
rectum.
[5]
 Worldwide more than half of the prevalence burden is found in the developed 
countries, although they only harbor one sixth of the world population.
[6]
 The incidence rises 
with industrialization and urbanization, supposedly due to increased risk factors that come 
with the Western life style, like higher consumption of meat and alcohol, as well as higher 
body mass.
[6]
 More than 50% of the Western population develops a colorectal tumor by the 
age of 70 and about 1 in 10 of these adenomas progresses to the malignant state.
[7]
  
For colorectal carcinoma, surgical resection remains the mainstay of treatment 
measures.
[8]




removal by polypectomy is fundamental for successful treatment. As colorectal tumors often 
give rise to symptoms at early stages of development, they are fairly treatable and the 
survival rate is relatively high.
[6]
 A treatment with established chemotherapeutics can be 
beneficial for the individual patient, dependent on the stage of the carcinoma, molecular 
markers, and metastatic potential.
[9,10]
 Nevertheless, in general the identification of predictive 
markers for patient stratification is difficult.
[11] 
About 85% of all colorectal tumors exhibit a mutation in the gene encoding the 
adenomatous polyposis coli (APC) protein.
[7]
 A mutation of this tumor suppressor is thought 
to be of pivotal importance for the initiation of colorectal cancer growth due to APCs central 
function as a negative regulator of the Wnt signaling pathway. The Wnt pathway activates 
several genes involved in fundamental cellular processes like proliferation, differentiation, 
and survival.
[12]
 The mutation on the APC gene is thought to be the first in a cascade of 
mutations that drive the oncogenic alteration from normal epithelium via adenoma to 
carcinoma.
[13]
 The sequence of genetic alterations is well described and the loss of APC 
function is often followed or accompanied by an activating mutation of K-Ras, which then 
induces the hyperproliferation of the epithelial cells even further. Subsequent loss of 
SMAD-4, a component of the TGF-β pathway, leads to the abrogation of the TGF-β-induced 
G1-cell cycle stalling. Late in colorectal tumor development, close to the manifestation of the 
carcinoma stage, the tumor suppressor p53 is mutated.
[14]
  
Despite the current understanding of the genetic background of colorectal cancer 
development and the fact that localized CRC is fairly treatable by resection, the optimization 
of an adjuvant therapy for pre- and post-resection treatment might improve the outcome of 




 The Chaperone Protein HSP90 1.3
Cancer cells in general have to cope with increased proteotoxic stress due to hypoxia 
in the microenvironment, conformationally aberrant oncoproteins, an increased amount of 
reactive oxygen species, and disproportionally expressed proteins due to chromosomal 
instability.
[16,17]
 These conditions lead to an elevated proportion of misfolded proteins in 
cancer cells and hence an increased dependence on chaperone machineries. These chaperone 
networks support the correct folding of proteins in cells challenged by proteotoxic stress and 
help to maintain the integrity of the proteome in cancer cells. One of the most important 






HSP90 is a largely cytoplasmic protein. Unlike other chaperones, HSP90 binds its 
client proteins in a late stage of folding, thereby helping these proteins to acquire and 
maintain their native structure.
[19]
 Compromising the function of HSP90 leads to the 
proteasomal degradation of its client proteins. Therefore, the chaperoning function of HSP90 
is essential in all eukaryotes. Its sequence is highly evolutionary conserved, e.g. in yeast 60% 
of the Hsp90 nucleotide sequence is identical to human Hsp90.
[20]
 HSP90 exists in two 
isoforms in human; HSP90, an inducible isoform, and HSP90β, which is constitutively 
expressed. The two isoforms differ only slightly in their functions and share the vast majority 
of their respective clients.
[21]
 Altogether their functional diversity is poorly understood.
[22]
 
Apart from these two cytosolic HSP90 isoforms, there are also homologues localized to the 
mitochondria (TRAP1) or the endoplasmic reticulum (GRP94), but both homologs are of 
minor importance and have not been studied thoroughly.
[23]
 
Under normal conditions HSP90 makes up to 2% of the cellular protein content and 
this portion is only about two-fold increased upon stress.
[18]
 A large and complex network of 
co-chaperones controls the HSP90 chaperone machinery thereby regulating its client 
specificity and activity, e.g. by client protein shuttling, induction of conformational change, 
or by binding, and stabilizing an intermediate state of the chaperoning cycle.
[24] 
The chaperone works as a homodimer in which two molecules of HSP90 dimerize at 
the C-terminal dimerization domains of the monomers.
[25]
 The client binding domain is in the 
middle part of the protein and the N-terminal region harbors the ATP-binding domain.
[26]
 
Upon binding of ATP the lid segment of the N-terminal domain closes and thereby promotes 
the dimerization of the N-terminal regions. This closed state of the two monomers adopts a 
twisted confirmation and the central parts of the two monomers form a surface at which most 
client interactions take place.
[27,28]
 The client protein binds to the closed conformation and the 
chaperoning process takes place together with a simultaneous ATP-hydrolysis. Upon release 




In the deep binding pocket of HSP90, ATP adopts a relatively unusual structure called 
the Bergerat fold. This unusual, kinked conformation is only observed in a few other 
ATPases and kinases, namely in gyrases, histidine kinases and the bacterial DNA mismatch 
repair proteins MutL.
[29]
 This specific arrangement of ATP permits the design of inhibitors 






     
Figure 1.1: The HSP90 chaperoning cycle (schematic, adapted from ref [23] and [32]).  
HSP90 homodimer shown in blue, client protein shown in magenta.  Formation of closed 
state upon binding of ATP.  Binding of the misfolded client protein to the chaperone. The 
chaperoning function is fulfilled upon hydrolysis of adenosine triphosphate (ATP). 
Co-chaperones govern the specificity and activity of HSP90.  Release of the correctly 
folded client protein and phosphate (Pi).  Open confirmation is regenerated upon release 
of adenosine diphosphate (ADP). 
 
 HSP90 Clients Involved in Cancer  1.4
The continuous research on HSP90 and its role in cancer gives rise to a long and ever 
growing list of known client proteins (see http://www.picard.ch/downloads/ 
Hsp90interactors.pdf). Many of these client proteins are conformationally labile signal 
transducers that have a crucial role in growth control, cell survival, or in developmental 
processes.
[19]
 The maintenance of these processes is crucial for the development of cancer. In 
this regard HSP90 is working as a buffer for the numerous genetic lesions present in cancer 
cells. The mutations lead to thermal instability of the proteins and in the absence of HSP90 
they are prone to misfold. The activity of HSP90 however, retains the function of mutated 
proteins and prevents the clients from proteasomal degradation.
[23]
 Due to the fact that 
mutated clients proteins depend on the HSP90 activity far more than the proteins in their 
native state, HSP90 inhibitors should show a higher impact on cancer cells which contain 




One group of HSP90 clients are key oncogenic proteins involved in the control of 
proliferation (e.g. Receptor tyrosine-protein kinase ErbB2/Her2, or Hepatocyte growth factor 
receptor Met), immortalization (e.g. telomerase), apoptosis (e.g. RAC serine/threonine-
protein kinase AKT), and angiogenesis (e.g.  Hypoxia-inducible factor 1-alpha HIF1α).
[18]
 
Also, the tumor suppressor p53 is a client of HSP90, and it can serve as an example for the 
change in the HSP90 ‒ client protein interaction after the client has become mutated. 
Aberrations of the TP53 gene (encoding p53) are the most common mutations in human 
cancers and the mutant forms are dependent on the HSP90 activity to a much larger extent 
compared to the wild-type form.
[33]
 Wild type p53 is subjected to a fast turnover by 
proteasomal degradation, whereas mutant p53 and HSP90 form a stable complex which 
prevents the ubiquitination of the tumor suppressor, thereby leading to the observed 
accumulation of mutant p53 protein within tumor cells.
 [34]
 The turn-about in p53 function, 
from a tumor suppressor in native form to an oncogenic driver when mutated, is commonly 
referred to as “gain-of-function” and the accumulation of mutant p53 protein is an essential 
feature of this cancer promoting character of mutant p53.
[34]
  
The fact that HSP90 is over-active in cancer cells makes it an interesting target for the 
treatment of cancer. The increased demand for HSP90 activity due to accumulation of 
mutated proteins leads to an overexpression of the chaperone and supposedly to the formation 
of large stabilized multichaperone complexes that include HSP90, co-chaperones, and client 
proteins.
[18]
 It is proposed that these complexes exhibit a much higher activity compared to 
HSP90 in normal cells.
[35]
 In order to maintain the function of several oncogenic proteins, 
tumor cells are thought to be addicted to the hyper-active HSP90 chaperone.
[36]
 Due to this 
hyperactivity of cancerous HSP90, the chaperone binds to its inhibitors with approximately 
100-fold higher affinity than in normal cells.
[37]
 This preference of HSP90 inhibitors for 
tumor cells, together with the already described oncogenic character of many HSP90 clients, 
the higher sensitivity of cells with mutated client proteins, and the fact that some of the 
HSP90 inhibitors accumulate in cancer, underscores the high potential of HSP90 inhibitors 




 Inhibition of HSP90 as a Cancer Therapy Approach 1.5
HSP90 inhibition is a vital field of research nowadays due to the promising prospects 
of this strategy for the treatment of cancers. The advantage over the established cancer 




tumor cells compared to cells in normal, healthy tissue.
[3]
 Therefore HSP90 inhibitors should 
not exhibit the major drawbacks of established chemotherapeutics that target the DNA 
replication or single molecules from signaling pathways (described in chapter 1.1).  
 
1.5.1 The First Generation of HSP90 Inhibitors: Derivatives of Geldanamycin  
The first HSP90 inhibitor, geldanamycin, is a natural compound from the bacteria 
Streptomyces hygroscopicus and was initially analyzed due to its weak antibiotic effect.
[41]
 
Following this, it was found to be an anti-cancer agent due to its ability to reverse the 
transformation of cells that was driven by v-Src. Later this observation was traced back to the 
inhibition of HSP90 activity by geldanamycin.
[42,43]
 The tyrosine-protein kinase transforming 
protein Src is an oncogenic protein and one of the numerous HSP90 clients among the 
receptors, kinases, and transcription factors involved in carcinogenesis.  
Geldanamycin and its derivative 17-N-allylamino-17-demethoxygeldanamycin 
(17-AAG) (structures in Figure 1.2) inhibit HSP90 by binding to its ATP-binding pocket and 
have been the subject of intensive research, including clinical trials.
[44]
 However, due to some 
major drawbacks including high hepatotoxicity, poor solubility, complications with 
formulation, relatively weak target potency, and low bioavailability, the evaluation of 
geldanamycin-derivatives as drugs for cancer treatment was stopped.
[45,46]
  
The high toxicity of geldanamycin compounds is caused by their quinone moiety. For 
this reason, and due to fact that the quinone form only represents a less active pro-drug of the 
inhibitors (see chapter 1.5.5 for details), a chemically reduced and stabilized hydroquinone 
form of 17-AAG called retaspimycin is now undergoing evaluation in clinical trials (structure 
in Figure 1.2). It has increased water solubility and bioavailability and is considerably less 





Figure 1.2: Chemical structures of geldanamycin derivatives. 
Geldanamycin, 17-N-allylamino-17-demethoxy-geldanamycin (17-AAG) and retaspimycin. 




However, the overall profound drawbacks for geldanamycin derivatives led to the 
intensive research for other HSP90 inhibitors; the so called second generation of HSP90 
inhibitors. 
 
1.5.2 The Second Generation of HSP90 Inhibitors: Small Synthetic Molecules 
The second generation of HSP90 inhibitors includes small synthetic molecules like 
ganetespib, NVP-AUY922, PU-H71 and SNX-2112, which all inhibit HSP90 by binding to 
its ATP-binding pocket. 
Ganetespib is a resorcinolic triazolone inhibitor (see structure in Figure 1.3) which is 
licensed by Synta Pharmaceuticals
®
 and shows promising properties for the application in 
cancer treatment. Currently, many clinical trials are in progress in various cancer types 
aiming to elucidate the feasibility of ganetespib as a clinical HSP90 inhibitor in combination 
with established cancer therapy treatments, i.e. cytostatics (docetaxel, capecitabine, 
paclitaxel, pemetrexed), a specific kinase inhibitor (crizotinib) or an estrogen receptor 
antagonist (fulvestrant).
[48]
 Additionally, ganetespib is evaluated as a single agent against 
tumors which rely on specific oncogenic drivers that are known HSP90 clients. Encouraging 
clinical activity has been observed in ALK-driven non-small cell lung cancer and Her2-
overexpressing breast cancers.
[49,50]
 Like all second generation inhibitors, ganetespib is more 
potent than inhibitors from the first generation. This advantage is partly due to its ability to 
bind the open as well as the closed conformation of the ATP binding pocket of HSP90, 
whereas the larger molecules from the first generation of inhibitors are limited to binding to 
the open conformation.
[40]
 Also, additional hydrogen bonds are formed with HSP90 via the 
triazolone moiety of ganetespib increasing its binding affinity, thereby surpassing the 
inhibitors from the first generation in terms of binding potential.
[40]
 Like all second 
generation inhibitors that are currently under investigation, ganetespib lacks the quinone 
moiety, which is known to cause the severe toxicity of geldanamycin and its derivatives. The 
consequence is an advantageous toxicity profile compared to first generation inhibitors.
[40]
  
Another second generation inhibitor is called NVP-AUY922 (AUY922). This 
compound is licensed to Novartis and is also based on resorcinol, here coupled to an 
isoxazole (Figure 1.3). This inhibitor was developed on the basis of high-throughput 
screening of a compound library followed by structure-based optimization.
[51,52]
 AUY922 is 




combination with the proteasome inhibitor bortezomib.
[46]
 It is also combined with 
monoclonal antibodies in breast cancer trials.
[46] 
The purine scaffold HSP90 inhibitor PU-H71 (see structure in Figure 1.3) was 
developed utilizing structure based drug design. In this approach new insights from crystal 
structure studies of HSP90 in binding complex with geldanamycin or with ATP were taken 
into account. When binding to HSP90, the adenine moiety of PU-H71 forms hydrogen bonds 
and adopts an orientation similar to ATP.
[53]
 In preclinical trials, PU-H71 has shown very 
good anti-tumor effects in both in vitro and in vivo settings, and there are currently phase I 
clinical trials ongoing to test its safety and tolerability in patients with solid tumors.
[46,54]
  
The HSP90 inhibitor SNX-2112 and its pro-drug form SNX-5422 were discovered by 
a chemoproteomics approach using an ATP-affinity column.
[55]
 It contains a dihydro-
indazolone derivate (see structure in Figure 1.3) and represents a unique class of HSP90 
inhibitors, structurally unrelated to the other compounds discussed previously. Although 
treatment with the drug showed very promising properties in preclinical trials, the 





Figure 1.3: Chemical structures of second generation HSP90 inhibitors.  





1.5.3 Rationale for the Clinical Use of HSP90 Inhibitors  
Almost all clinical trials with HSP90 inhibitors aim at the application of the inhibitors 
in combination with established chemotherapeutics to treat cancer.
[46]
 Due to the fact that 
HSP90 is protecting the cells under stress conditions such as induced during chemotherapy, 
the inhibition of this protective machinery sensitizes the cells to the effects of 
chemotherapeutics.  
The list of HSP90 clients includes the Serine/threonine-protein kinase Chk1 and the 
Wee1 protein kinase, two key players from the DNA damage response that regulate the 
transition through the G1-S and G2-M checkpoints and ensure the interruption of DNA 
synthesis when DNA lesions are present.
[58]
 Therefore, HSP90 inhibitors could lead to the 
degradation of Chk1 and Wee1, which would in turn sensitize the cells to chemotherapeutics 
by abrogation of the G1/S arrest.
[59,60]
  
Furthermore, the HSP90 client RAC serine/threonine-protein kinase (AKT) is 
involved in the regulation of metabolism, proliferation, cell survival, growth, and 
angiogenesis.
[61]
 The loss of this regulatory protein by HSP90 inhibition has been shown to 
sensitize the cells to induction of apoptosis by paclitaxel.
[62]
  
In addition, the HSP90 clients AKT and Her2, together with the kinase Raf-1, are 
involved in the protection of cancer cells against γ-radiation induced cell death.
[63,64,65]
 The 
inhibition of HSP90 causes the degradation of these γ-radiation activated proteins, followed 




As already described in chapter 1.4 the tumor suppressor p53 is a client of HSP90. 
This tumor suppressor is mutated very frequently in tumors and it has been observed that 
mutant p53 is forming stabilized complexes with HSP90, which prevent the proteasomal 
degradation of mutant p53.
[34]
 The inhibition of Hsp90 could overcome this stabilization and 
lead to a decrease of the oncogenic effect that is caused by the accumulation of mutant p53. 
 
1.5.4 Potential Risks Linked to the Clinical Use of HSP90 Inhibitors 
In the light of all this cancer affecting impact, the inhibition of HSP90 seems very 
beneficial for treatment of cancer. However, there are some implications that might give rise 
to undesirable side effects of HSP90 inhibition.  
Firstly, HSP90 has a broad spectrum of clients and an exact prediction of the 




lot of factors like genetic background of the patient, site and stage of the tumor, as well as 
stress levels and activated signaling pathways in the individual cells. 
For some inhibitors it has been described that they lead to a short term induction of 
some client proteins, prior to their degradation. This can give rise to unwanted side effects 
following the release of these clients.
[67,68]
  
HSP90 also plays a regulatory role in the heat shock response where, under stress-free 
conditions it binds and represses the heat shock transcription factor 1 (HSF1). Upon stress or 
inhibition of HSP90, HSF1 is released. This then trimerizes and binds heat shock elements to 
activate the heat shock response. Part of this heat shock response is the increased expression 
of Hsp27 and Hsp70 which may then serve to compensate for the loss of HSP90.
[69]
 Also, 
HSF1 has been shown to increase the oncogenic potential of cancer cells, as it regulates the 
expression of numerous other genes that are involved in cell survival under stressful 
conditions.
[70]
 Therefore, the activation of HSF1 might give rise to side effects or the 
development of resistance to Hsp90 inhibitors. Cisplatin has been shown to block the binding 
of HSF1 to the heat shock elements, which partly explains the synergistic effect observed 
when it is used in combination with HSP90 inhibitors.
[71]
  
Another aspect is that HSP90 also works as a buffer to maintain normal function of 
mutated proteins. Therefore in some cases upon inhibition of HSP90 the severe effects of 




1.5.5 Varying Pharmacology of Different HSP90 Inhibitors 
For all second generation HSP90 inhibitors, the elucidation of their pharmacology is 
still in progress, but some significant differences are already apparent. Ganetespib, AUY922, 
and PU-H71 are currently in clinical trials and seem to have different effects on the spectrum 
of HSP90 client proteins.
[53]
 Furthermore, they differ in their tumor cell retention and half-life 
in vivo.
[53]
 Nevertheless, even for short-lived HSP90 inhibitors it has been shown that they 
can induce the degradation of the relevant clients.
[44]
 The HSP90 inhibitor-treated cells then 
might need several days to resynthesize these proteins. Therefore, even the short–lived 
HSP90 inhibitors might have a long lasting pharmacodynamic effect.
[44]
 
The resorcinol-based inhibitors ganetespib and AUY922 show quite similar behavior 
as they interact with the ATP-binding pocket of HSP90 by forming almost identical hydrogen 
bonds.
[72]




ganetespib due to its retention in photoreceptor cells.
[73]
 This phenomenon makes AUY922 
less favorable for use in therapy compared to ganetespib. 
While for ganetespib the tolerability of efficient doses has been demonstrated in 
previous studies, the elucidation of drug tolerance for PU-H71 is still ongoing. Phase I 
clinical trials and a metabolism study based on positron emission tomography are in progress 
to understand the drugs pharmacokinetics.
[74]
  
Any effects which might compromise the impact of a given drug have to be known 
and need to be considered before its administration as a new standard therapy. For instance, 
some proteins or enzymes which are highly expressed in different tumor types might affect 
the activity or the uptake and efflux of the drug. On the other hand, the lack of enzymes 
responsible for systemic metabolism of the drug can lead to severed effects caused by 
accumulation of the drug in the body.  
The enzyme that determines the outcome of geldanamycin drug treatment is known 
and has been studied quite intensely. The activities of geldanamycin and all drugs derived 
from it, except for retaspimycin, depend on the reduction of their less active quinone form of 
the pro-drug to the more potent hydroquinone form. For example 17-AAG gets reduced to its 
more active metabolite 17-AAGH2.
[75]
 This reduction is facilitated by the NADPH-quinone 
oxidoreductase 1 (NQO1), which has previously been identified as a potential biomarker for 
geldanamycin derived HSP90 inhibitors. A tumor that lacks this enzyme is prone to exhibit 
resistance to treatment with the drug.
[76]
  
For other chemotherapeutics various response-related biomarker are already known, 
which are associated with the route of systemic drug metabolism in the human body. For 
instance, the uracil analog 5-fluorouracil, which is widely prescribed for colorectal cancer, is 
dependent on hepatic dihydropyrimidine dehydrogenase (DPD) for its metabolism. Patients 
with low DPD activity in the liver cannot efficiently inactivate 5-FU and the active drug 
accumulates in the patients in amounts that can cause lethal toxicity.
[77]
 Also, thiopurine 
drugs such as thioguanin are dependent on the activity of thiopurine methyltransferase 




However, in current clinical practice the screening for genetic polymorphisms that 
influence the drug metabolism is rare and almost exclusively done for patients that exhibit 
unexplained adverse effects or lack of response.
[79]
 This ‘trial-and-error’ approach for 
chemotherapeutic drug dose adjustments can be risky for the patients with certain genotypes 






The drug metabolizing enzymes employed by the human body for turnover of 
xenobiotic compounds, might determine the outcome of a drug treatment, by lack or excess 
of drug activating or deactivating entities. Therefore, enzymes of this class are of particular 
interest when examining the pharmacodynamics of a new drug.  
 
 Enzymes of the Drug Metabolism  1.6
The gastrointestinal tract (GI tract) is the organ system, in which foodstuff and 
xenobiotic compounds such as drugs are metabolized. Whereas nutrients are absorbed and 
further processed for digestion, potentially harmful xenobiotics are subjected to a series of 
metabolizing reactions to deactivate them and facilitate their excretion.
[80]
 The liver, the colon 
and virtually all tissues throughout the GI tract are known to express enzymes involved in 
drug metabolism. Therefore cells derived from organs from the GI tract, such as the CRC cell 
lines used in this study, exhibit much higher drug metabolizing potential compared to cells 
derived from other, less metabolically active tissues.  
The metabolism of compounds, regardless of their origin being endogenous or 
exterior, is facilitated in two phases of conversion. Reactions of the phase I of the drug 
metabolism introduce reactive and polar groups to their substrates by oxidation, reduction, or 
hydrolysis. In phase II the substrates are subjected to conjugation, in which charged moieties 
are coupled to these reactive sites of the usually hydrophobic target molecules.
[80]
 Substrates 
that undergo these processes usually become deactivated and their water solubility is 
increased to support their excretion. Nevertheless, some cases of bio-activation of pro-drugs 




1.6.1 Enzymes from the Phase I of the Drug Metabolism 
Among the enzymes facilitating phase I reactions the superfamily of cytochromes 
P450 (CYPs) represents the most important one as they facilitate the first step of metabolism 
for the vast majority of therapeutic drugs. CYPs carry out oxidation, hydroxylation, 
dehalogenation, dealkylation, and deamination reactions during the metabolism of dietary and 
xenobiotic compounds as well as during the synthesis of endogenous compounds.
[80]
 The 
twelve CYP isoforms, which are known to be involved in drug metabolism, are able to 








The phase I enzymes from the superfamily of the flavin-containing monooxygenases 
are of less importance compared to CYPs, as they only oxidize a small fraction of xenobiotic 
compounds and they most often produce benign metabolites.
[80]
  
Another group of enzymes that participate in the phase I of drug metabolism are the 
hydrolytic enzymes, which are comprised of the epoxide hydrolases and the 
carboxylesterases. The epoxide hydrolases deactivate potentially toxic epoxides which, if left 
unattended, would bind to cellular nucleophiles such as DNA, RNA or proteins, causing 
severe effects. Carboxylesterases hydrolyze ester and amide containing chemicals. They are 
not only involved in drug deactivation processes, but on the contrary often yield a more 
reactive species. For instance the pro-drug irinotecan is bioactivated by carboxylesterases to 





1.6.2 Enzymes from the Phase II of the Drug Metabolism 
Phase II of the drug metabolism is facilitated by enzymes catalyzing substrate 
conjugation reactions. Among these transfer reactions, the addition of glucuronic acid, 
sulfate, glutathione, or small acetyl or methyl groups are the most important ones. 
The phase II enzyme with the broadest spectrum of xenobiotic substrates, the 
uridinediphospho(UDP)-glucuronosyltransferase (UGTs), are discussed in more detail in 
chapter 1.6.3. 
Another major phase II reaction is sulfate transfer, which is facilitated by the 
sulfotransferases that conjugate sulfates from the co-substrate 3´-phosphoadenisine-5´-
phosphosulfate onto hydroxyl- and amine-groups of the targets. The sulfotransferases 
metabolize a wide variety of endogenous and exogenous compounds and play an important 
role in human homeostasis. Drug metabolism by sulfation often leads to chemically more 
reactive compounds that can form electrophilic cations upon heterolytic cleavage.
[80]
  
The conjugation of substrates by glucuronidation and sulfation yields metabolites with 
significantly increased water solubility, thereby leading to the accumulation of the 






The transfer of glutathione moieties to electrophilic substrates is catalyzed by the 
glutathione-S-transferases and serves to protect cellular macromolecules from these reactive 
species.
[83]
 The co-substrate for this phase II enzymes is the tripeptide glutathione, which is 
present in the cells in its oxidized (GSSG) and reduced (GSH) form. The ratio of GSH:GSSG 
determines the maintenance of the reductive environment in cells.
[80]
 Polymorphisms in 
glutathione-S-transferases genes are associated with increased susceptibility to 
carcinogens.
[83]  
Transferases that conjugate substrates with small moieties like acetyl groups and 
methyl groups play only a minor role compared to the other classes of phase II enzymes 
discussed here. From a clinical perspective the most important methyltransferases is the 
thiopurine S-methyltransferase (TPMT) as it catalyzes the S-methylation of aromatic and 
heterocyclic sulfhydryl compounds and some drugs used in cancer treatment are subject to 




1.6.3 The UDP-Glucuronosyltransferases and Their Role in Drug Metabolism 
The bulk of the phase II reactions in drug metabolism are facilitated by UDP-
glucuronosyltransferases (UGTs), which deactivate their substrates by transferring a 
glucuronate moiety from UDP-glucuronic acid onto hydrophilic side chains. These target 
groups can be hydroxyl, carboxyl, carbonyl, sulfuryl, or amine moieties.
[80]
 Like the phase I 
enzymes described in chapter 1.6.1, the UGTs are localized to the luminal site of the 
endoplasmic reticulum.
[80]
 They are highly expressed in the liver where the majority of 
metabolizing reactions take place.
[84]
 
The superfamily of UGTs can be divided in two smaller groups; the UGT1A and the 
UGT2B families.
[85]
 While the UGT2B enzymes primarily target endogenous compounds, 
such as steroids, the UGT1A enzymes have a broad spectrum of xenobiotic substrates.
[80]
 
Among these are many well-studied and intensively utilized drugs.
[86]
  
The UGT1A family consists of nine isoforms that differ in substrate specificity 
(Figure 1.4). The UGT1A gene locus is encoded on chromosome 2 and spans nearly 200 kb. 
Over 150 kb consists of a tandem array of exon regions that encode the N-terminus of the 
individual UGT1A isoforms. These first exons encode the protein region that is responsible 
for substrate recognition and the individual expression of the isoforms is regulated by 
adjacent promoters in an inducible and tissue-specific manner. The C-terminal fractions of 




and which are shared by all isoforms.
[87]
 The splicing process that yields individual isoforms 
is facilitated by a splice site on the 3´-end of the first exon, which is spliced to the 5´-end of 
the second exon. During the transcription process exons of other isoforms encoded in 
between are considered to have an intronic character and therefore play no role in the 
subsequent splicing process where the first exon of the transcribed isoform is linked to the 
common exons two to five.
[88]
  
                     
 
Figure 1.4: The UGT1A gene locus (adapted from ref [80]) 
For transcription of a specific UGT1A isoform, the individual first exon (black box) is spliced 
to the common exons 2 to 5 (gray boxes).  
 
The isoforms of UGT1A can be divided into clusters due to their sequence 
similarities. The isoforms 3 through 5 and the isoforms 7 through 10 comprise a cluster 
respectively. The isoforms 1 and 6 are individual isozymes with no high similarity to other 
UGT1As.
[89]
 The high similarity in the two isozymes clusters of the UGT1A family implies 




As observed for most drug metabolizing enzymes, the UGT1A locus harbors several 
genetic polymorphisms which are associated with severe loss of enzyme activity. For 
instance, a homozygosity for a dinucleotide (TA) insertion in the UGT1A1 gene promoter 
region resulting in variant allele (TA)7 (designated as UGT1A1*28) and leads to an decreased 




is bilirubin, a breakdown product of the heme metabolism. A defect in the glucuronidation of 
this product leads to elevated serum levels or hyperbilirubinemia, leading to a clinical 
symptom called jaundice i.e. yellowish skin.
[80]
 The loss of UGT1A1 activity by the 
UGT1A1*28 polymorphism results in severe hyperbilirubinemia, a condition termed Gilberts 
symdrome. The phenomenon of increased serum levels of bilirubin is also observed, when 
drugs are administered that require the metabolism by UGT1A1. These drugs can compete 
with bilirubin for the metabolism by UGT1A1 and the combination of substrates can exceed 




In some rare cases the conjugation by UGT enzymes has an activating effect on the 
substrates, as is observed with morphine for example. This widely used opioid analgesic 
becomes biologically activated upon glucuronidation to the 6-O-glucuronide by UGT2B7.
[90]
 
Conversely, morphine becomes deactivated when glucuronidated at the 3-OH position by 
UGT1A1, UGT1A3, UGT2B1 or UGT2B7. This illustrates the rather complex effect such 
metabolizing reactions might have on a xenobiotic compound with pivotal effects on the 







 Scope of the Thesis 1.7
The promising prospects of HSP90 inhibition for treatment of cancer led to the 
development of a range of interesting small molecule inhibitors, many of which are currently 
in clinical trials. The expedient application of these drugs demands a thorough understanding 
of their pharmacokinetics and pharmacodynamics. The basis for the complete comprehension 
of the drug effects is the elucidation of all cellular processes that influence the drug 
distribution, the interaction with the target, the drug turnover and potential side effects of the 
drug. This understanding could provide the basis for efficient treatment of cancer patients, 
and could minimize the potential risk for patients in advance to the treatment. 
The objective of this study was to ascertain the factors that determine the outcome of 
ganetespib treatment in CRC cell lines. For the clinical application it would be of immense 
importance to know the features of colorectal cancer that classify for a treatment with 
ganetespib or that dictate the amount of inhibitor that needs to be administered.  
Interestingly, a previous study in which the gene expression of a broad spectrum of 
human cancer cell lines has been correlated to their susceptibility to various cancer drugs has 
been shown to be a useful tool for the detection of drug-related biomarkers (see ref. [91]). For 
instance, Barretina and coworkers predicted the dependence of 17-AAG susceptibility on 
NQO1-activity. The fact that this known drug-activation mechanism (described in chapter 
1.5.5) was found by the comparative analysis can be seen as a prove-of-principal for the 
approach of the study. The correlation between drug susceptibility and gene expression data 
can be used for the detection of biomarkers that predict the response to treatment. 
A similar correlation of the ganetespib susceptibility of the panel of CRC cell lines 
with gene expression data of the cells should provide a list of genes with potential influence 
on the ganetespib sensitivity of the cells. Therefore, the initial aim of this study was the 
elucidation of ganetespib susceptibility of a panel of CRC cell lines. The gene expression 
data were available from microarrays that were performed previously on the CRC cell lines 
by Spitzner and coworkers (see ref. [92]). 
In the work presented here gene candidates from this correlation of gene expression 
and ganetespib susceptibility should be tested for their actual influence on ganetespib efficacy 
in the CRC cells including the mechanisms by that such genes affect drug sensitivity. The 
identification of a drug-related biomarker from this list of relevant genes would prove very 
helpful for the clinical application of the drug in treatment of colorectal cancer. 
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2.   Materials and Methods 
 Materials 2.1
2.1.1 Technical Devices 
 
Table 2.1: Technical Devices  
Device  Company  
Agilent 1100 HPLC Agilent Technologies, Santa Clara, CA 
API 4000 tandem mass spectrometer  Applied Biosystems, Foster City, CA 
Blotting chamber  Biozym, Hessisch Oldendorf, Germany  
C1000 CFX96 real-time PCR thermocycler Bio-Rad Laboratories  
Cell counting chamber Neubauer improved  Brand, Wertheim, Germany  
Centrifuge 5415R  Eppendorf, Hamburg, Germany  
Centrifuge 5810R  Eppendorf  
Centrifuge Megafuge 1.0R  Heraeus, Thermo Scientific, Waltham, MA, 
United States  
Chemiluminescence imager Chemocam HR 
16 3200  
Intas Science Imaging Instruments, Göttin-
gen, Germany  
Cytometer Celigo  Brooks Automation, Inc.Chelmsford, MA, 
United States  
Electrophoresis system, for SDS-PAGE  Amersham Biosciences, GE Healthcare, Lit-
tle Chalfont, United Kingdom  
FACS machine Guava PCA-96 Base System  Millipore, Merck, Darmstadt, Germany  
Freezer -20°C  Liebherr, Bulle, Switzerland  
Freezer -80°C  Heraeus, Thermo Scientific  
Heating Block  Grant Instruments, Hillsborough, NJ, United 
States  
Ice-machine B100  Ziegra, Isernhagen, Germany  
Kinetex 2.6 µm C18 column  Phenomenex, Torrance, CA 
Laminar flow cabinet Hera Safe  Heraeus, Thermo Scientific  
Liquid nitrogen tank LS 4800  Taylor-Wharton, Theodore, AL, United 
States  
Magnetic stirrer MR Hei-Standard  Heidolph, Schwabach, Germany  
Magnetic stirrer MR3001  Heidolph  
Microscope Axovert 40C  Zeiss, Oberkochen, Germany  
Microscope, Axioscope 2 Plus  Zeiss  
Microwave  Cinex, Lippstadt, Germany  
Mini Centrifuge MCF-2360  LMS, Tokyo, Japan  
pH-meter WTW-720  WTW, Weilheim, Germany  
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Pipets Eppendorf Research Series 2100    
(0.1-2.5μl; 0.5-10μl; 10-100μl; 100-1,000μl)  
Eppendorf  
Refrigerator 4°C  Liebherr  
Roller RM5 V-30  CAT, Staufen, Germany  
Rotator PTR 300  Grant Instruments  
Scales Acculab ALC-6100.1  Sartorius, Göttingen, Germany  
Scales LE623S  Sartorius  
Scanner CanoScan 8600F  Canon, Tokyo, Japan  
Shaker PROMAX 2020  Heidolph  
Sonication device Bioruptor  Diagenode, Liège, Belgium  
Spectrophotometer NanoDrop ND-1000  PeqLab, Erlangen, Germany  
Thermomixer comfort  Eppendorf  
Vacuum pump  IBS Integra Biosciences, Fernwald, Germany  
Vortex Genie 2  Scientific Industries, Bohemia, NY, USA 




Table 2.2: Consumables  
Product  Company  
12-well plates for microscopy  Corning, Corning, NY, United States  
96-well plates for qPCR  4titude, Wotton, United Kingdom  
Cell culture flasks (25cm², 75cm²,125cm²)  Greiner, Frickenhausen, Germany  
Cell culture plates (6-well, 12-well)  Greiner  
Cell scraper (16cm, 25cm)  Sarstedt  
Cryo tubes Cryoline  Nunc, Thermo Scientific  
Filter tips (10μl)  Starlab, Hamburg, Germany  
Filter tips (20μl, 200μl, 1,000μl)  Sarstedt  
Optical covering foil for qPCR plates 4titude 
Parafilm  Brand  
Pipet tips (10μl, 20-200μl, 1,000μl)  Greiner  
Protran nitrocellulose transfer membrane  Whatman, Dassel, Germany  
Reaction tube (0.2mL)  Sarstedt  
Reaction tube (0.5mL, 1.5mL, 2.0mL)  Eppendorf  
Reaction tube (15mL, 50mL)  Greiner  
Safe-lock reaction tube (1.5mL)  Eppendorf  
Sterile filter  Millipore, Merck  
Syringe  Henke-Sass, Wolf, Tuttlingen, Germany  
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2.1.3 Chemicals and Reagents 
 
Table 2.3 Chemicals and Reagents 
Substance  Company  
Acetic acid  Roth, Karlsruhe, Germany  
Acrylamide-bisacrylamide  Roth  
Albumin Fraction V (Bovine Serum 
Albumine, BSA)  
Roth  
Ammonium persulfate (APS)  Roth  
Ammonium sulfate ((NH4)2SO4)  Roth  
Ampicillin Sigma-Aldrich 
Aprotinin  AppliChem  
Bromophenol blue  Sigma-Aldrich  
Calcium chloride dihydrate (CaCl2 x 
2H2O)  
Roth  
Chloroform  Roth  
Dimethyl sulfoxide (DMSO)  AppliChem  
Dithiotreitol (DTT)  Sigma-Aldrich  
DNA ladder  Fermentas, Thermo Scientific  
Deoxynucleotide triphosphates (dNTPs)  Bio-Budget, Krefeld, Germany  
Ethanol 99.8%  Roth  
Ethanol 99.9% p.a. Merck  
Ethylene diamine tetraacetatic acid 
(EDTA)  
Roth  
Ethylene glycol tetraacetic acid (EGTA)  Roth  
Glycerol  Roth  
Glycine  Roth  
Glycogen  Fermentas, Thermo Scientific 
Glycogen blue  Ambion, Life Technologies  
HEPES  Roth  
Hydrogen chloride (HCl)  Roth  
Isopropanol  Th. Geyer, Renningen, Germany  
Lipofectamine 2000  Invitrogen, Life Technologies  
Magnesium chloride (MgCl2) for PCR  Fermentas, Thermo Scientific  
Magnesium chloride hexahydrate 
(MgCl2 x 6H2O) 
Roth  
Methanol >99%   Roth  
Milk powder  Roth  
Nonidet P-40 substitute (NP-40)  Sigma Aldrich  
Nuclease free water  Ambion, Life Technologies  
Pefabloc SC  Roth  
Pepstatin A  AppliChem  
Ponceau S  Roth  
Potassium chloride (KCl)  Roth  
Potassium glutamate (KGlu)  Roth  






Prestained Protein Ladder  Fermentas, Thermo Scientific  
Random hexamer primers Thermo Scientific 
RNase inhibitor  Fermentas  
Rotiphorese Gel 30  Roth  
Sodium acetate (NaAc)  Roth  
Sodium bicarbonate (NaHCO3)  Roth  
Sodium chloride (NaCl)  Roth  
Sodium deoxycholate  AppliChem  
Sodium dodecyl sulfate (SDS)  Roth  
Sodium hydrogenphosphate 
heptahydrate (Na2HPO4 x 7H2O)  
Roth  
Sodium hydroxide (NaOH)  Sigma-Aldrich  
SYBR green  Invitrogen, Life Technologies  
Tetracycline  Sigma-Aldrich  
Tetramethylethylenediamine (TEMED)  Roth  
Trehalose  Sigma-Aldrich  
Trisamine (Tris)  Roth  
Triton X-100  AppliChem  
TRIZOL Invitrogen, Life Technologies  
Tween 20  AppliChem  




Table 2.4: HSP90 Inhibitors  
Compound  provider CAS-Number Molecular weight 
17-AAG NCI 75747-14-7 585.7 
Ganetespib Synta Pharmaceuticals
®
 888216-25-9 364.4 
NVP-AUY922 Selleckchem 1051919-22-2 465.54 
PU-H71 TOCRIS 873436-91-0 516.87 
SNX-2112 Selleckchem 908112-43-6 464.48 
 
Short name of NVP-AUY922 is AUY922. Chemical structures shown in Figure 1.2 and 
Figure 1.3. Stock solutions of 170 mM (17-AAG) or 5mM (all other inhibitors) were 
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2.1.3.2 Buffers and Solutions 
 
Table 2.5: Buffers and Solutions 
Buffer / Solution  Components  
BSA solution  5% BSA  
dissolved in TBST  
Cell lysis buffer  100% Ripa lysis buffer  
2M Urea  
1μg/mL Aprotinin  
1μg/mL Leupeptin Hemisulfat  
1μg/mL Pepstatin A  
1mM Pefabloc SC  
0.5μg/mL Microcystin  
Laemmli buffer, 6x  0.35M Tris, pH6.8  
30% Glycerin  
10% SDS  
9.3% DTT  
0.02% Bromphenol blue  
dissolved in H2O 
PBS, pH 7.4  24mM NaCl  
0.27mM KCl  
0.81mM Na2HPO4 x 7H2O  
0.15mM KH2PO4  
dissolved in H2O  
TBS/T, pH 7.5  50mM Tris  
150mM NaCl  
0.1% Tween 20 (TBST only) 
dissolved in H2O  
qPCR reaction buffer, 10x  750mM Tris-HCl, pH 8.5  
200mM (NH4)2SO4  
0.1% Tween 20  
dissolved in H2O 
qPCR reaction mix, 25x  1x qPCR reaction buffer 10x  
3mM MgCl2  
1:80,000 SYBR Green  
0.2mM dNTPs  
20U/mL Taq polymerase  
0.25% Triton X-100  
300mM Trehalose in 10mM Tris, pH 8.5  
dissolved in water  
Ripa lysis buffer, pH 7.5  1% Triton X-100  
1% Na deoxycholat  
0.1% SDS  
150mM NaCl  
10mM EDTA  
SDS running buffer 25 mM Tris 
86.1 mM glycin 
3.5 mM SDS 
dissolved in water 
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Western blot blocking solution 5% milk powder 
dissolved in TBT/T 
Western blot buffer 25 mM Tris 
192 mM glycin 
20% methanol 
dissolved in water 
2.1.3.3 Enzymes and Kits 
 
Table 2.6 Enzymes and Kits 
Name Company 
BCA Protein Assay Kit Thermo Scientific 
DNase I, hc (50u/µL) Thermo Scientific 
DNase I buffer Thermo Scientific 
Immobilon Western HRP Substrate Peroxide 
Solution 
Millipore, Merck 
NucleoBond® AXG Macherey Nagel, Düren, Germany 
RT Buffer (5x) Thermo Scientific 
Revert Aid Reverse transcriptase (RT) (200 u/µL) Thermo Scientific 
SuperSignal West Femto Maximum Sensitivity 
Substrate 
Thermo Scientific 




Table 2.7: Primary Antibodies 









































1:1,000  Santa Cruz 
(all diluted in TBST with 5% skimmed milk powder) 
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Table 2.8: Secondary Antibodies 
Name Cat.No. Company 
HRP-coupled AffiniPure 
F(ab')2 fragment, anti-
mouse IgG (H+L) 
711-036-152 
Jackson Immunoresearch, 
Europe, Newmarket, UK 
Goat anti-rabbit IgG-HRP sc-2004 Santa Cruz 
(all diluted in TBST with 5% skimmed milk powder) 
 
2.1.4 Eukaryotic Cell Culture 
2.1.4.1 Cell Lines  
 
Table 2.9: Carcinoma Cell Lines used in the Study 
Name                 Origin 
CaCo2 Colorectal carcinoma (colon) 
HCT116 Colorectal carcinoma (colon) 
HT29 Colorectal carcinoma (colon) 
LS1034 Colorectal carcinoma (cecum) 
LS411N Colorectal carcinoma (cecum) 
LS513 Colorectal carcinoma (cecum) 
SW1463 Colorectal carcinoma (rectum) 
SW403 Colorectal carcinoma (colon) 
SW480 Colorectal carcinoma (colon) 
SW620 Colorectal carcinoma (colon,derived from metastasis in lymph node) 
SW837 Colorectal carcinoma (rectum) 
 
2.1.4.2 Media and Supplements for Eukaryotic Cell Culture 
 
Table 2.10: Media and Supplements 
Name  Company 
RPMI 1640 medium Gibco, life technology 
Dulbecco’s Modified Eagle Medium (DMEM), 
powder 
Gibco, life technology 
Fetal calf serum (FCS) Thermo Scientific  
L-glutamine Gibco, life technology 
PBS (tablets) Gibco, life technology 
Penicilin / Streptomycin Gibco, life technology 
Trypsin / EDTA Gibco, life technology 
Ciprofloxacin Bayer, Leverkusen, Deutschland 
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For full medium (RPMI 1640-full):  - 10% fetal calf serum (FCS) 
- 2 mM L-glutamin 
- 50 units/mL penicillin 
- 50μg/mL streptomycin 
- 10 μg/mL ciprofloxacin 
2.1.5 Bacteria 
For the amplification of the plasmids the E. coli DH10B (Invitrogen) strain was used. 
 
2.1.6 Bacteria Culture Medium 
All bacteria were grown in lysogeny broth (LB) medium: 
for 1 liter LB medium:  - 10 g peptone 
- 5 g yeast extract 
- 10 g NaCl 
- pH was adjusted to 7 (with NaOH)  
- water was added  
- sterilized at 121°C for 15min 
For plates 1.5% agar was added. For bacteria selection ampicillin (200μg/mL) was added. 
 
2.1.7 Oligonucleotides and plasmids 
2.1.7.1 Primers for Human Gene Expression Studies 
 
Table 2.11: Sequences of the Primers used in qPCR 
Target forward primer  reverse primer 
UGT1A ATCTGCTTGGTCACCCGATG TCCATGCGCTTTGCATTGTC 
UGT1A1 GCCATTCCAAAGGGAGGATGTG TGGGAACAGCCAGACAAAAGC 
UGT1A3-5 CATAATGAGGCCCTGATCAGGC AATCGACAGGTACTTAGCCAG 
UGT1A6 GCTGGTGGTCCCTCAGGAC CAGCTCTTCTTGGTCATACGGC 
UGT1A7-10 CACAGTGCCCTGCTCCTC GTTTGGAGAATTTCAGAGGCTATTTC 
HPRT1 ATGCTGAGGATTTGGAAAGG TCATCACATCTCGAGCAAGAC 
HPRT1 = Hypoxanthine-guanine phosphoribosyltransferase 
  











s75 S231075 GGUAAAAUUUUGAACCAUUtt AATGGTTCAAAATTTTACCtt 
s76 S231076 GGAUCAAUGGUCUCAGAAAtt UUUCUGAGACCAUUGAUCCca 
scr #4390844 Silencer
®
 Select Negative Control No. 1 siRNA (Sequence not published) 
 
All siRNAs were ordered from ambion
®





For the expression of UGT1A10 and -Gal in human cancer cells, the pCMV-
SPORT6 expression vector was used. This vector contains an ampicillin resistance site that 
confers resistance to ampicillin in E. coli. The genes are expressed under control of the 
human cytomegalovirus (CMV) promoter and a SV40 polyadenylation site ensures poly A 
capping. 
For the expression of GFP in the cells, a pcDNA3 vector was used. It features the 




For the confluence measurements of the plates the celigo
®
 software was used.  
All calculations concerning the IC50 determination, the expression level quantification 
by qPCR, and the generation of the graphs were done using Microsoft Excel
®
 2010.  
The statistical analysis was performed by Frank Kramer using the free statistical 









2.2.1 Cell Biology 
2.2.1.1 Cultivation of Adherent Human Cells 
Adherent human cells were cultured in coated cell culture plates at 37°C, 5% CO2 and 
in a humidified atmosphere in full RPMI 1640 medium. 
The cell lines were split 2-3 times per week. Hence, after the medium was sucked off, 
cells were washed with pre-warmed PBS and detached by incubation with pre-warmed 
trypsin/EDTA at 37°C for a couple of minutes. After complete detachment of all cells the 
enzymatic reaction of trypsin was stopped by adding fresh culture medium. Finally, a portion 
of the trypsinized cells was transferred to a new cell culture dish and supplemented with 
fresh, pre-warmed RPMI 1640 culture medium. 
 
2.2.1.2 Freezing / Thawing of Adherent Cells 
For the long-term storage of cells in liquid nitrogen, low numbers of cell passages 
were used. For freezing, cells were trypsinized, and centrifuged (5 min, 800 rpm at RT). 
Afterwards, the cells of one whole 10 cm-plate were resuspended in 400 µL freezing medium 
(10% DMSO in FCS) and the cell suspension was transferred into cryo vials. To ensure slow 
and gradual lowering of the temperature the vials were incubated in a freezing container filled 
with isopropanol over night at -80°C. On the following day the vials were transferred into 
liquid nitrogen for long time storage. 
For thawing, the cells were quickly defrosted using pre-warmed medium and 
transferred to a 10 cm-plate with 10 mL RPMI 1640 medium. The medium was changed 
when the cells were adherent, to remove the toxic DMSO from growing cells. 
 
2.2.1.3 siRNA-Mediated Knockdown of Gene Expression 
UGT1A mRNA was knocked down in SW1463 and HT29 cells using commercially 
available siRNA (sequences see Table 2.12). For transfection of one well on a 6-well plate, 
50 pmol siRNA were added to 250 µL DMEM without any supplements (= DMEM (-)). 
Separately, 5 µL Lipofectamine 2000 was added to 250 µL DMEM (-). Both mixtures were 
vortexed for 10 s and incubated for 5 min at RT. The mixtures were combined, vortexed for 
10 s and incubated for 20 min at RT. In the meantime cells were trypsinized and counted. The 
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prepared mixture of siRNA and lipofectamine 2000 was spread across the well and 200,000 
to 400,000 cells were added drop-wise to the well. Subsequently, each well was filled up with 
2 mL of full RPMI medium and incubated over night at 37°C. On the next day the medium 
was changed. 24 to 48 h after the knockdown, cells were either transferred to 12-well plates 
for confluence measurement (see chapter 2.2.1.6) or to 96-well plates for viability 
measurement (see chapter 2.2.1.8), or they were harvested for RNA expression analysis by 
qPCR (see chapter 2.2.2.6) or protein level analysis by immunoblotting (see chapter 2.2.3.1).  
 
2.2.1.4 Transfection of Cells with Plasmids for Transient Overexpression 
UGT1A or -Gal was overexpressed in SW480 and HCT116 cells from a pCMV-
SPORT6 expression vector. For transfection of a 6-well, 2.5 µM of the plasmid were added 
to 250 DMEM without any supplements (= DMEM (-)). Separately, 5 µL Lipofectamine 
2000 were added to 250 µL DMEM (-). Both mixtures were vertexed for 10 s and incubated 
for 5 min at RT. The mixtures were combined, vortexed for 10 s and incubated for 20 min at 
RT. In the meantime cells were trypsinized and counted. The prepared mixture of vector and 
lipofectamine 2000 was spread across the well and 200,000 to 400,000 cells were added 
drop-wise to the well. The volume was filled up to 1 mL with DMEM (-). After 4 h of 
incubation at 37°C the medium was changed for full RPMI medium.For determination of 
transfection efficiency a GFP expression vector was added to the expression vector in a 1/10 
ratio. 
24 to 48 h after the transfection the cells were either transferred to 12-well plates for 
confluence measurement (see chapter 2.2.1.6) or to 96-well plates for viability measurement 
(see chapter 2.2.1.8), or protein level analysis by immunoblotting (see chapter 2.2.3.1) after 
treatment with ganetespib.  
 
2.2.1.5 Treatment of the Cells with Inhibitors  
Cells were treated with various HSP90 inhibitors, applied in full RPMI 1640. For 
17-AAG a 170 mM stock solution was prepared in DMSO and aliquoted. The aliquots were 
diluted 1:33 to prepare the 5 mM solutions used for treatment. For all other HSP90 inhibitors 
(ganetespib, AUY922, SNX-2112, PU-H71) stock solutions with 5 mM concentrations were 
prepared in DMSO. From these stocks the concentrations needed were achieved by dilution 
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in RPMI 1640 medium. For all applications RPMI with a DMSO concentration comparable 
to the highest treatment concentration was used as a control. 
 
2.2.1.6 Confluence Measurement with the Celigo® Cytometer 
Cells were seeded on 12-well plates (100,000 cells/well, except for CaCo2, LS513 
and SW1463 200,000 cells/well) 24 h before treatment. The celigo
®
 machine was used to 
take microscopic pictures of the cells at 0, 24, 48, and 72 h after beginning of the treatment. 





2.2.1.7 Calculation of the IC50 Values 
The determination of concentrations that were needed to diminish the growth rate of 
the cells to the half maximum (IC50), was based on the confluence measurements. When the 
confluence of the cell is plotted over the three day-time course, the growth rate representative 
for the according inhibitor concentration can be deduced from the slope of the linear 
regression line of the graph (Figure 2.1 a). 
When plotting the growth rate against the inhibitor concentration (Figure 2.1 b), the 
IC50 can be approximated by linear regression and calculation of the inhibitor concentration 
(x) for which the growth rate (y) equals half the value of the y-axis intersection (x = y/2).  
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Figure 2.1: The calculation of IC50 values from the confluence measurements.  
(a) Example of the deduction of the growth rate in dependence of the inhibitor concentration 
(ganetespib concentration in HT29 cells). The growth rates are deduced from the slope of the 
regression lines when confluence is plotted over time of the treatment. (b) Growth rates are 
plotted against inhibitor concentration, the IC50 concentration is calculated from the 
regression line. 
 
2.2.1.8 Viability Assay  
For measuring the viability of the cells, they were transferred to a 96-well-plate 24 h 
after transfection. 5,000 cells (HCT116, SW480) or 10,000 cells (HT29) were seeded in 
triplicate one day before treatment with ganetespib. Cells were treated for 48 h and subjected 
to the CellTiterGlo
®
 Luminescent Cell Viability assay (Promega, Madison WI, USA) 
according to the manual of the manufacturer. This luciferase assay determines the ATP 
concentration in the cells and thus reflects cell viability. 
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2.2.1.9 LC-MS/MS Analysis of Drug Metabolites 
The LC-MS/MS study was performed by David A. Proia, Suqin He, and Luisa Shin 
Ogawa (all employees of Synta Pharmaceuticals
®
, Lexington, Kentucky, USA). They 
assessed levels of metabolized and unmetabolized ganetespib and AUY922 from cell lysates 
as well as from supernatant medium. Therefore the CRC cells were treated with 1 μM of the 
according drug for 5, 15, 30, 60 or 480 min. At each time point, media was collected and cell 
lysates were generated for subsequent bioanalysis of secreted and intracellular concentrations 
of ganetespib and its glucuronides, or AUY922 and its glucuronides. Equal protein 
concentrations from cell lysates or equal volumes of media were used for the bioanalysis.  
Samples were extracted by protein precipitation with methanol containing the internal 
standards ([13C, 3H3]-ganetespib and [13C, 3H3]-ganetespib glucuronides), and 33nalysed 
by LC-MS/MS using an Agilent 1100 HPLC interfaced to an API 4000 tandem mass 
spectrometer. The separation of AUY922 and its glucuronide were performed on a Kinetex 
2.6 µm C18 (30 x 2.1 mm) column. Detection was accomplished in the positive electrospray 
ionization mode by selected reaction monitoring of the mass transitions. Quantitation was 
done by extrapolation from standard curves. Due to the lack of the authentic reference 
material, concentrations of AUY922 glucuronide were reported as analyte/internal standard 
peak area ratios. 
 
2.2.2 Molecular Biology 
2.2.2.1 Transformation of Thermo-Competent E. coli  
Plasmids used for overexpression experiments were transformed in heat-shock 
competent E. coli DH10B. Hence, 50 μL of the bacteria were mixed with 100 ng DNA and 
incubated on ice for 30 min. Cells were subsequently incubated for 10 min at 37°C and 
cooled down on ice for 10 min. After addition of 950 μL LB medium the bacteria were kept 
at 37°C for 30 min and subsequently plated on LB agar containing Ampicillin (200 μg/mL) 
and incubated overnight at 37°C. On the next day, a single colony was picked and expanded 
by an overnight culture in 50 mL LB medium containing 100 µg/mL ampicillin. Finally the 
plasmid was extracted using the PureYield™ Plasmid Midiprep System (Promega), according 
to the manual of the manufacturer (see chapter 2.2.2.2). 
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2.2.2.2 Midi-Preparation of Plasmid DNA 
Midi-preparation of DNA from a 50 mL overnight culture was performed using the 
PureYield™ Plasmid Midiprep System kit from Promega as recommended by the 
manufacturer. Binding and washing of the membrane was performed under vacuum. Finally 
the DNA was eluted using 200 µL nuclease-free water. The concentration was measured 
using the nanodrop spectrophotometer. Plasmids were stored at -20°C. 
 
2.2.2.3 Primer Design 
For design of the qPCR primers, the templates were retrieved from the NCBI web site 
(http://www.ncbi.nlm.nih.gov/gene/). The primers for UGT1A isoform cluster amplification 
were designed manually based on sequence alignments and checked for their specificity using 
the primer BLAST function on the ncbi web site (http://www.ncbi.nlm.nih.gov/tools/primer-
blast/). Basis for this platform is the primer3 software.  
The criteria that were applied for the primer design and parallel quality check-up: 
Product size:    100 – 250 bp  
Primer size:    18 – 24 nucleobases 
GC content:   40 – 60% 
Melting temperature:  58 – 62°C 
Max poly X:   5.00 
Max self-complementarity:  3.00 
GC clamp:   1 
The nucleotides (see Table 2.11) were ordered from metabion (www.metabion.com).  
 
2.2.2.4 Quality Control of Primer 
Prior to the use of the primers in standard qPCR reactions (protocol see below in 
chapter 2.2.2.5), they were checked for efficiency and specificity. Therefore a dilution series 
of cDNA (1:20, 1:40, 1:80) was used as template for real-time PCR analysis for each primer 
pair.  
From the Ct values the efficiency of the primer was calculated. As the 1:2 dilution of 
the cDNA should result in a Ct difference of 1.00. Primers that did not fulfil this quality 
criterion were rejected.  
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A high specificity of the primers was ensured by a sharp peak of the melting curve. 
Shoulders or multiple peaks of the curves were not observed with the primers, indicating the 
amplification of a specific product. 
 
2.2.2.5 Quantitative Real-Time PCR 
The qPCR was performed in 96-well format. Each well contained the reaction mixture 
with the according primer. The temperature cycling program was used in the Chromo4 PCR 
machine. 
 
Table 2.13: Composition of Real-Time PCR Mixture 
Compound 
Volume                          
(per 25 µL reaction) 
qPCR reaction mix, 25x (self-made, see Table 2.5) 14 µL 
Primer solution (containing both primers at concentration of 10µM)   1 µL 
Nuclease free water    5 µL 
cDNA (1:20 dilution)   5 µL 
 
Table 2.14: Thermocycler Program 
Step Temperature Time  
1 95°C 3 min  
2 95°C 15 s  
3 58°C 45 s  
4 Return to step 2  x40  measurement 
5 95°C 1 min  
6 Melting curve + 0.5°C/s measurement at every step 
 
2.2.2.6 Isolation of Total RNA 
Total RNA was isolated using TRIZOL and used for subsequent reverse transcription 
and quantification by PCR.  
The cells on the 6-well plates were washed with PBS. After removal of PBS, 600 µL 
of TRIZOL were added directly to the wells for cell lysis. After 2 min of incubation, the 
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TRIZOL was transferred to 1.5 mL Eppendorf tubes and the RNA was either stored at -80°C 
for later RNA purification or directly subjected to the steps necessary for RNA isolation: 
120 µL chloroform were added to the 600 µL TRIZOL. The samples were shaken, 
incubated for 3min at RT and centrifuged to separate the different phases (15 min, 12,000 g, 
4°C). The RNA containing aqueous upper phase was transferred carefully into a fresh 
Eppendorf tube and purified by precipitation with 500 μl isopropanol. The samples were 
shaken and centrifuged (30-60 min, 12,000 rpm, 4°C). Subsequently, the pellet was washed 
twice with 75% Ethanol (5 min, 7,500 rpm, 4°C). The supernatant was completely removed 
carefully and the pellet was air-dried. The RNA was dissolved in 20 μl nuclease free H2O and 
heated for 5 min at 55°C. The concentration and purity of the RNA was measure using the 
nanodrop spectrophotometer. All RNA samples were treated with Dnase to remove residual 
genomic DNA contaminations (see chapter 2.2.2.7).  
 
2.2.2.7 Dnase I Digest of RNA Samples 
To ensure a complete removal of any possible contamination of genomic DNA, a 
Dnase I digest was performed. Therefore the RNA sample was diluted to 100 µL with 
nuclease-free water, mixed with 20 µL Dnase I mix (see Table 2.15) and incubated at 37°C 
for 30 min, shaking. 
 
Table 2.15: Dnase I Mix (prepared as mastermix for multiple samples) 
Compound Volume 
10x Dnase I Buffer 12 µL 
Dnase I, hc 0.25 µL 
RNase inhibitor 1 µL 
Nuclease-free water 6.75 µL 
  
After incubation the samples were purified by a phenol-chloroform extraction. 
Therefore, 120 µL of a phenol-chloroform (5:1, pH 4.3) mix were added to each RNA sample 
and vortexed for 10 s. After short centrifugation of the tubes (1 min, 13,000 rpm at 4°C) the 
upper aqueous phase was transferred to a new Eppendorf tube and mixed with 375 µL 96% 
ethanol and 17 µL of a sodium acetate solution (3 mol/L) for RNA precipitation. The samples 
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were incubated at -80°C for one hour and centrifuged for 30 min (13,000 rmp at 4°C). After 
removal of the supernatant, the resulting RNA pellet was washed with 150 µL 70% ethanol. 
The pellet was air-dried and resuspended in 20 µL nuclease-free water. The RNA was stored 
at -80°C. 
 
2.2.2.8 cDNA Synthesis 
The concentration of the RNA samples was measured at a wavelength of 260 nM 
using the nanodrop spectrophotometer. 1 µg of RNA was used for the cDNA synthesis. In an 
Eppendorf tube 2 µL of a mix of random hexamer primers and 1 µL dNTP mix (10 mM of 
dATP, dCTP, dGTP, and dTTP each) were added. The reaction volume was filled up to 
16 µL with nuclease-free water. The mix was heated up to 70°C for 5 min, subsequently 
centrifuged shortly and kept on ice. A master was prepared containing (per reaction) 2 µL of 
Reaction Buffer (10x), 0.25 µL RNase Inhibitor (10 U), 0.125 µL M-MuLV reverse 
transcriptase (25 U) and 1.625 µL nuclease-free water. 4 µL of the mastermix were added to 
each sample and the tubes were incubated at 42°C for 1 h. Afterwards the enzyme was 
deactivated by incubation at 95°C for 5 min. The reaction was diluted to 400 µL (1:20 
dilution) prior to use in qPCR reactions. The cDNA was stored at -20 °C. 
Because a DNA digest on the RNA was performed prior to the cDNA synthesis, there 
was no need to run a control without any reverse transcriptase in order to exclude 
contaminations by genomic DNA.  
 
2.2.2.9 Quantification of Relative Gene Expression 
The mRNA expression levels of diverse cellular genes were quantified by performing 
qPCR. Three independently extracted RNA / cDNA samples were used for every 
experimental condition (biological replicas). Technological replicas were included in the 
biological replicas. Reactions were pipetted according to Table 2.13 in a low profile 96-well 
plate. The plate was sealed with optical foil, vortexed and centrifuge shortly (1 min, 800 rpm, 
RT). All plates were prepared freshly and analysed directly after pipetting. The thermocycler 
program was applied as used for primer validation (Table 2.14). 
Subsequently, the CT method was applied for the calculation of the relative gene 
expression. Therefore, the threshold was manually set and the relative Ct values for the 
reference and the target genes were obtained. To account for variations in the pipetting 
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process, all analysis were performed in triplicates. The reference gene (HPRT1) was always 
analysed in parallel to ensure comparability between plates. 
The Ct values were calculated by subtraction of the target gene Cts against the 
reference gene Cts for normalization. Next, the Ct values were calculated by subtracting 
the control sample values from the values of treated or knockdown samples and the Ct 
value of the control sample was set to 0 (= fold change). Ct values resemble logarithmic 
values to the basis of 2. Hence, the mean log ratio was calculated by using the 
formula: -2
(-Ct)
. Control or untreated samples were therefore set as 1, whereas up- or down-
regulation are represented by a mean log-ratios of >1 or ranging between 0 - 1 respectively. 
 
2.2.3 Protein biochemistry  
2.2.3.1 Protein Harvest 
For protein preparation, adherent cells were scraped off directly in the culture 
medium, transferred to 2 mL Eppendorf tubes and centrifuged for 5 min (1,500 rpm, RT). 
The cell pellet was washed with ice cold PBS and centrifuged as before. The cells were lysed 
in cell lysis buffer. The amount of lysis buffer added (between 100 and 300 µL) was adjusted, 
depending on the amount of cells in the pellet. All cell lysates were kept on ice and were 
subjected to 15 min of sonication in the bioruptor at maximum intensity (30 sec on/off 
interval) in ice cold water, to disrupt any bulky genomic DNA. After sonication the protein 
concentration of all samples was analysed using the BCA method (see chapter 2.2.3.2). The 
protein samples were stored at -80°C.  
 
2.2.3.2 Determination of the Protein Concentration 
Protein concentration was measured using the BCA Protein Assay Kit. The 
determination of protein amount based on the biuret reaction was performed according to the 
manufacturer´s instructions. In short, a master mix of 4% cupric sulfate and BCA solution 
(1:50) was added to the protein lysates (1:20) and incubated for 30 min at 37°C. Afterwards 
the concentration was measured with Nanodrop. For calculation of absolute concentrations, a 
standard curve was measured in parallel with defined concentrations of albumin. 
 




To separate proteins under denaturing conditions, SDS-PAGE was performed as 
developed by Shapiro and coworkers as well as Laemmli (see ref [94] and [95]). Separation 
of the proteins relies on their electrophoretic mobility, and separates them by their size. Prior 
the electrophoresis the proteins are boiled in presence of sodium dodecyl sulfate (SDS). The 
SDS coats the proteins, which leads to a negative over-all charge. Hence, the proteins move 
to the anode if an electric field is applied. The rate at which the proteins move through the 
pores of the gel depends on the protein size. 
Basically the SDS-PAGE is performed using two layers of gel: the stacking gel and 
the separation gel. The stacking gel (5% acrylamide at pH 6.8) contains large pores and the 
proteins are forming a stack between the leading chloride ions and the trailing ion Glycine. 
This leads to sharp protein bands. In the separation gel (10% acrylamide at pH 8.8) the 
proteins are separated according to their molecular weight.  
 
Table 2.16: Composition of SDS Gels (mixture for four gels) 
Component Separation gel Stacking gel 
H2O 13.2 mL 6.8 mL 
Acrylamide (30%) 16.0 mL 1.7 mL 
1.5 M Tris                 10.0 mL (pH 8.8)                 1.25 mL (pH 6.8) 
SDS (10%)   0.4 mL 0.1 mL 
APS (10%)   0.4 mL 0.1 mL 
TEMED       0.016 mL   0.01 mL 
 
First the separation gel was casted between two glass plates, which were separated by 
two spacers. The gel was topped with isopropanol during the polymerization to ensure the 
generation of a sharp gel front and prevent air contact and dehydration. After the 
polymerisation, the stacking gel mixture was prepared and was filled on top. To form 
separated pockets for the application of the protein samples, a comb with 10 or 15 teeth was 
put in the liquid mixture prior to polymerization. 
The protein concentrations of the samples were adjusted to the lowest protein 
concentration and 6x Laemmli buffer was added. For protein denaturation, the samples were 
boiled for 3 min at 95°C and subsequently applied to the pockets of the stacking gel, next to a 
pre-stained protein marker. The electrophoresis was performed at 20 mA per gel. 
After appropriate separation of the proteins, the proteins in the gel were transferred to 
nitrocellulose membrane by applying the immunobloting technique. 




After separation by SDS-PAGE the proteins have to be transferred onto a 
nitrocellulose membrane, to make them more accessible for the staining with antibodies.  
This transfer was performed in a cassette composed of two outer layers of sponges 
and three layers of Whatman-paper. Inside of the cassette, the gel was stacked onto the 
nitrocellulose membrane and the cassette was put into a blotting chamber. The gel was 
oriented towards the cathode and the membrane was pointing towards the anode. By applying 
a current of 100 V for 2 h, the proteins were transferred to the membrane. The whole process 
was performed in the cold room and the chamber was surrounded with ice, to prevent over-
heating.  
After the transfer, the membranes (or so called blots) were blocked in 5% milk/TBST 
for 30 min at RT. The blocking prevents unspecific attachment of antibodies to the blot. The 
blots were subsequently incubated with dilutions of primary antibodies (see Table 2.7) either 
over night or at least for 4 h at 4°C in falcon tubes on a roller. After extensive washing (twice 
with 5% milk in TBST, twice with TBST for 10 min each), the blots were incubated with 
secondary antibody (in 5% milk in TBST) for 1 h at RT, rotating. After the same sequence of 
washing steps as before, the membrane was stained with Millipore staining solution and 
analyzed using the chemiluminescence detection machine Chemocam HR 16 3200 imager. 
 
2.2.4 Statistical Analysis 
The statistical analysis of the gene expression patterns and their correlation with drug 
sensitivities was performed by Frank Kramer from the department of statistical 
bioinformatics (Group of Prof. Tim Beissbarth in the department of medical statistics, 
University Medical Center Göttingen). For this analysis the mRNA expression levels were 
analyzed using log2 transformation and quantile normalization.
[96]
 Except for control spots, 
all 43,376 features were used without any a priori filtering. In order to determine significant 
differences of expression levels between the pooled groups of ganetespib-sensitive and 
ganetespib-resistant cell lines, a moderated Student's t test was computed on a gene-by-gene 
basis. Frank Kramer applied an empiric Bayes estimator to compute the linear models for 
thousands of genes in parallel and assess their significance.
[97]
 The gene list in the appendix is 
showing all genes of statistical relevance with a p-value of <0.005 and additional hits relevant 
for this work (chapter 6.1). 
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  In order to not exceed a false-discovery rate (FDR) of 5%, the p-values were adjusted 
for multiple testing using the Benjamini-Hochberg method.
[98]
 All analyses were performed 








3.   Results 
 
 Expression of UGT1A Correlates with Resistance to Ganetespib Treatment 3.1
Ganetespib is a second generation HSP90 inhibitor, proved to efficiently inhibit tumor 
progression in various cancer types. Therefore we wanted to dissect how different CRC cell 
lines respond to treatment with the inhibitor.  
To elucidate the different responses to ganetespib, the IC50 for eleven CRC cell lines 
were determined by a proliferation assay based on confluence measurements with the celigo
®
 
cytometer (see chapters 2.2.1.6 and 2.2.1.7). We determined two groups of cell lines with 
vast differences in their tolerance to ganetespib (Figure 3.1 a, blue bars). SW1463 and HT29 
cells are able to withstand concentrations in the micro molecular range of ganetespib (1.6 and 
2.5 µM respectively), whereas the other nine cell lines already respond to ganetespib in the 
nano-molar range. 
Therefore, a statistical analysis was conducted by Frank Kramer (department of 
statistical bioinformatics, University Medical Center Göttingen) on whole genome gene 
expression profiles which had been elucidated previously for all these cell lines (see 
ref. [92]). To determine significant differences in expression levels of single genes between 
the pooled groups of ganetespib-sensitive and ganetespib-resistant cell lines, Frank Kramer 
computed a moderated Student's t-test on a gene-by-gene basis. This comparison of gene 
expression patterns revealed a list of candidate genes, whose level of gene expression 
correlated with the ganetespib susceptibility in the CRC lines (see chapter 6.1), gene hits with 
a p-value <0.005 are shown).  
Among these genes with statistically relevant expression difference between 
ganetespib-resistant and -sensitive cell lines, UGT1A stood out due to its known function in 
drug metabolizing processes. The three UGT1A probes on the microarray (designated as 
UGT1A6 and UGT1A8 in the list of gene hits in chapter 6.1) were designed to bind the 
UGT1A mRNA in the common exons 2-5 and were therefore able to bind all nine isoforms of 
UGT1A (see chapter 1.6.3 for detailed description of the gene locus).  
To assess whether the in vitro mRNA levels of UGT1A of the eleven CRC cell lines 
reflect the expression distribution suggested by the microarray analysis, mRNA was isolated 
from the cell lines, reversely transcribed to cDNA and analyzed by quantitative RT-PCR 




distinguished by their expression levels of UGT1A. The ganetespib-resistant cells exhibit 
high levels of UGT1A mRNA expression (Figure 3.1 a, red bars). Also, they had high levels 
of UGT1A protein compared to ganetespib sensitive cell lines, as determined by immunoblot-
analysis (Figure 3.1 b). This hints at a causal link between the presence of UGT1A and the 
resistance to ganetespib treatment. 
 
Figure 3.1: Ganetespib resistance correlates with high expression levels of UGT1A in 
CRC-derived cell lines.  
(a) Resistance to ganetespib correlates with high mRNA expression of UGT1A. The growth 
inhibitory concentration of ganetespib was determined for 11 cell lines derived from CRC 
(blue columns). Total mRNA was extracted from the eleven CRC cell lines, reverse-
transcribed, and subjected to qPCR analysis. Relative mRNA levels of all UGT1A isoforms 
were determined (red columns, Ct values were normalized to values of HPRT1 expression). 
The error bars represent the standard deviation. Correlation between ganetespib resistance 
and UGT1A expression levels was highly significant (sample Pearson correlation coefficient 
r = 0.957). (b) Ganetespib-resistant cell lines SW1463 and HT29 express UGT1A protein at 
high levels. UGT1A protein levels were determined by immunoblot analysis for the same cell 






 UGT1A Knockdown Sensitizes Resistant CRC Cell Lines to Ganetespib 3.2
To check whether UGT1A expression contributes to the observed resistance to 
ganetespib, a siRNA-based knockdown was established in HT29 cells, the cell line with the 
most profound ganetespib resistance. The siRNA treatment led to a knockdown of the 
UGT1A mRNA (Figure 3.2 a), which was sufficient to strongly reduce the protein levels for 
four days (Figure 3.2 b). 
To determine the effect of UGT1A knockdown on proliferation upon ganetespib 
treatment, the confluence of the cells after siRNA treatment and subsequent treatment with 
ganetespib over three days was measured (Figure 3.2 c). The data show that in cells that were 
treated with UGT1A siRNA the growth was significantly diminished at ganetespib 
concentrations as low as 250 nM. On the other hand, the growth of the cells treated with 
scrambled siRNA remained unaffected even at ganetespib concentrations as high as 750 nM. 
These results indicate that the UGT1A knockdown is sensitizing the cells to ganetespib 
treatment. We further analyzed the effect of UGT1A knockdown on the viability of 
ganetespib treated HT29 cells using the ATP based CellTiterGlo
®
 Luminescent Cell Viability 
assay (Figure 3.2 d). A difference in the cell viability between cells treated with scrambled 
siRNA and UGT1A-siRNA was visible at a ganetespib concentration of 250 nM.  
In case that UGT1A expression affects the overall inhibition of HSP90 by ganetespib, 
HSP90 clients should degrade much faster in ganetespib-treated, UGT1A-depleted cells. 
Therefore we detected changes in the levels of the direct HSP90 client AKT and 
phosphorylated ERK, which can function as a read out for the activity of its HSP90-
dependent upstream activators RAF and BRAF. The levels were assessed by an immunoblot 
analysis in the presence of ganetespib (Figure 3.3). Whereas the control knockdown did not 
exhibit a relevant decrease of the levels of the client proteins even at high concentrations of 
ganetespib, the cells that were subjected to a UGT1A knockdown prior to the ganetespib 
treatment, showed a strong reduction in the levels of client protein. Thus, we conclude that 
the knockdown of UGT1A renders the resistant HT29 cells susceptible to the treatment with 
ganetespib, which provides the first evidence for the causal link between high UGT1A 







Figure 3.2: UGT1A knockdown renders HT29 cells more susceptible to ganetespib.  
HT29 cells were transfected using Lipofectamine 2000 with two different siRNA 
oligonucleotides against UGT1A (designated s75 and s76) and a control scrambled siRNA 
(designated scr). Subsequently UGT1A mRNA and protein levels were determined by qPCR 
(a, HPRT1 expression levels were used for normalization, error bars indicate standard 
deviation, asterisks show significance by Student´s t-test; *** = p<0.005) and immunoblot 
analysis (b, GAPDH as loading control) at t = 24 h and 96 h after start of knockdown. 
(c) UGT1A knockdown renders HT29 cell less tolerant to ganetespib treatment. 24 h after 
siRNA transfection, ganetespib was added to the cells at the indicated concentrations; 
ganetespib-containing medium was refreshed every 24 h. Cell confluence was determined by 
quantitative light microscopy (Celigo
®
) 72 h after first addition of the drug. * = p<0.05, 
** = p<0.01, *** = p<0.005 (Student’s T-test). (d) Knockdown of UGT1A in HT29 cells 
decreased cell viability upon ganetespib treatment. Upon treatment as in a, cell viability was 
determined by assessing the ATP concentration in cell lysates using the CellTiterGlo
®
 





Figure 3.3: UGT1A knockdown in HT29 cells destabilizes HSP90 clients upon ganetespib 
treatment. 
HT29 cells were first transfected with siRNA for 24 h, followed by incubation with different 
concentrations of ganetespib for 36 h and immunoblot analysis of HSP90 clients. To avoid 
inactivation of ganetespib by glucuronidation through residual UGT1A, ganetespib-
containing media were renewed after 3, 6, 9, 12 and 24 h during the incubation period. 
 
 Overexpression of UGT1A10 Renders Sensitive Cells Resistant to Ganetespib 3.3
Treatment 
As UGT1A is expressed in 9 different isoforms, we hypothesized that only a subset of 
these isoforms might be responsible for the detected ganetespib resistance by 
glucuronidation. Therefore, we analyzed the mRNA levels of UGT1A gene clusters by 
selective RT-PCR analysis. The groups of UGT1A isoforms (UGT1A3, -4, -5 and UGT1A7, 
-8, -9, -10, see Figure 3.4 a) are characterized by a high similarity and the gene expression of 





Therefore we quantified the mRNA levels of the similar isoforms by using primers 
that recognize all isoforms of one group (for primer sequences see chapter 2.1.7.1, for a 
detailed description of the gene locus see chapter 1.6.3). This analysis revealed that the 
cluster composed of isoforms 3, 4 and 5 as well as the cluster of isoform 7, 8, 9 and 10 are 
expressed at particularly high levels in the ganetespib-resistant cell line HT29 (Figure 3.4 b). 
Consequently, we hypothesized that these clusters are responsible for ganetespib resistance. 
To test this, isoform 10 was chosen as an example for these clusters and was overexpressed in 




Figure 3.4: Two clusters of UGT1A isoforms are expressed at high levels in ganetespib-
resistant cell lines.  
(a) Structure of the UGT1A gene locus. The two indicated clusters form due to the high 
similarity of the first exons of the isoforms 3-5 and 7-10 (adapted from ref [80]). (b) 
Expression of UGT1A isoforms in CRC cell lines. qPCR was performed to determine the 
different isoforms of UGT1A present in the different cell lines, using primers detecting the 
isoforms UGT1A1 (blue), UGT1A3-5 (red), UGT1A6 (green) and UGT1A7-10 (purple). The 
mRNA levels of HPRT1 were used for normalization of the Ct values. The error bars 





Monitoring the confluence of the cells after 72 h of ganetespib treatment, either with a 
plasmid encoding for UGT1A10 or β-Galactosidase (β-Gal) as an control, revealed a 
significantly increased tolerance to ganetespib in the presence of UGT1A10 (Figure 3.5 a). 
Similar results were obtained analyzing the UGT1A10 and β-Gal overexpressing cells with 
the CellTiterGlo
®
 luminescent cell viability assay (Figure 3.5 b). The presence of UGT1A10 
in the cells increased the tolerance to ganetespib and therefore enhanced the ATP-levels after 
48 h of ganetespib treatment.  
 
 
Figure 3.5: Overexpression of UGT1A10 leads to ganetespib-resistance. 
(a) UGT1A overexpression renders sensitive cell lines less susceptible to ganetespib 
treatment. SW480 and HCT116 cells, both sensitive to ganetespib, were transfected using 
Lipofectamine 2000 to overexpress UGT1A10. Cells were subsequently treated with 
ganetespib for 72 h. The confluence was determined with the Celigo
®
 Imaging Cell 
Cytometer. Asterisks show significance by student´s t-test * p<0.05, ** p<0.01, *** p<0.005. 
(b) Ganetespib-sensitive cells retain cell viability despite presence of ganetespib when 
UGT1A10 is overexpressed. The viability of SW480 and HCT116 cells was determined 48 h 
after ganetespib treatment using the CellTiterGlo
®
 luminescent cell viability assay as in 





UGT1A overexpression and its effect on client protein levels after ganetespib 
treatment were evaluated by immunoblot analysis (Figure 3.6). Indeed, stabilization of 
HSP90 client proteins was observed in UGT1A overexpressing cells at ganetespib 
concentrations usually efficient to inhibit HSP90 chaperoning function. Concluding, 
overexpression of the isoform UGT1A10 results in a higher ganetespib tolerance of normally 
ganetespib-sensitive cells. 
 
Figure 3.6: HSP90 client proteins are stabilized in ganetespib sensitive cell lines upon 
UGT1A10 overexpression.  
SW480 cells (top) and HCT116 cells (bottom) were transfected with a pCMV-SPORT6 vector 
encoding for UGT1A10 or β-Galactosidase (β-Gal, control). Subsequently, cells were 
subjected to the indicated concentration of ganetespib for 48 h before harvest and 
preparation of total protein lysates. The HSP90 client proteins Wee1 and AKT were stained, 
as well as phosphorylated ERK (p-ERK) and total levels of ERK. GAPDH was stained as a 
loading control. 
 
 Verification of Ganetespib Glucuronidation by LC-MS/MS  3.4
The observed ganetespib resistance caused by UGT1A10 suggests that this HSP90 
inhibitor is subject to glucuronidation by the transferase. To test whether the conjugation of 
ganetespib with glucuronic acid does take place in cells resistant to the drug, the 
corresponding metabolites were detected by LC-MS/MS analysis within the framework of 
cooperation with Synta Pharmaceuticals
®




employees of Synta Pharmaceuticals
®
, Lexington, Kentucky, USA) performed LC-MS/MS 
analyses on cell lysates and media supernatants from ganetespib-sensitive (SW480, HCT116) 
and -resistant cells (SW1463, HT29). The levels of unconjugated and glucuronated 
ganetespib were measured kinetically over 8 h. A fast turnover of ganetespib by 
glucuronidation was evident by a decrease in ganetespib levels and a rise in ganetespib 
glucuronides in samples from ganetespib resistant cells, whereas the levels of unconjugated 
ganetespib were stable in cells sensitive to the drug treatment (Figure 3.7). The kinetics for 
ganetespib metabolism were slower in SW1463 compared to HT29, with ~190 nM and 
13 nM ganetespib present respectively after 8 h. This difference in glucuronidation potential 
reflects the different levels of UGT1A expression in these two lines (Figure 3.1) and the 
resultant lower ganetespib resistance of SW1463 cells compared to HT29 cells (IC50 of 
1,582 nM versus 2,503 nM respectively).  
   
Figure 3.7: Ganetespib is a substrate for UDP-glucuronosyl conjugation by tumor cells. 
SW480, HCT116, SW1463 and HT29 cells were treated with 1 μM ganetespib. Cell lysates 
and culture media were collected at 5, 15, 30, 60 and 480 min. The total concentration of 
ganetespib and its glucuronidated metabolites in the lysates (a) and the supernatant media 
(b) were determined by LC-MS/MS (experiments were performed by David Proia, Suqin He, 




In addition, a similar bioanalysis was performed on cell lysates and supernatant of 
HCT116 and HT29 cells treated with AUY922, another resorcinol-based HSP90 inhibitor. 
An analogous accumulation of AUY922-glucuronide in the supernatant medium of HT29 
cells was detected, whereas the HCT116 cells were unable to glucuronidate the drug (Figure 
3.8). Due to the lack of the authentic reference material, concentrations of AUY922-
glucuronide are given as analyte/internal standard peak area ratios. 
 
Figure 3.8: Ganetespib is a substrate for UDP-glucuronosyl conjugation by tumor cells. 
HCT116 and HT29 cells were treated with 1 µM AUY922. Cell lysates and culture media 
were collected at 5, 15, 30, 60 and 480 min. The total concentration of AUY922 and its 
glucuronidated metabolites in the lysates (a) and the supernatant media (b) were determined 
by LC-MS/MS. The levels of glucuronidated AUY922 are given as AUY922 glucuronide peak 






 UGT1A Expression Levels do not Correlate to Susceptibility to the First 3.5
Generation Inhibitor 17-AAG  
To test whether UGT1A expression could also cause resistance to another, structurally 
unrelated first generation HSP90 inhibitor, the IC50 values for 17-AAG were determined in 
this panel of eleven CRC cell lines (Figure 3.9). Comparison of the UGT1A expression levels 
to the 17-AAG IC50 values reveals that the ganetespib-resistant cell lines HT29 and SW1463 
are susceptible to 17-AAG treatment and only the ganetespib sensitive cell line CaCo2 is able 
to withstand high concentrations of 17-AAG (IC50 >5 µM). The determined IC50 values for 
17-AAG do not correlate with UGT1A expression, indicating that the susceptibility to this 
HSP90 inhibitor is dependent on different mechanism than UGT1A-catalyzed 
glucuronidation.  
 
Figure 3.9: 17-AAG resistance does not correlate with UGT1A expression levels. 
 The same cell lines described in Fig. 1A were assayed for 17-AAG sensitivity (green bars) 
using the same cell proliferation assay as described in the legend to Fig. 1A and results were 
compared to UGT1A mRNA levels (red bars) as determined in Fig 1A. The error bars 
represent the standard deviation from three independent biological replicates. 
 
Furthermore, the protein levels of HSP90 clients from ganetespib sensitive cell lines 
SW480 and HCT116 and the ganetespib-resistant cell lines SW1463 and HT29 were 
analyzed after treatment with ganetespib and 17-AAG (Figure 3.10). Ganetespib addition 
leads to a reduction of the levels of HSP90 clients in ganetespib-sensitive cells, whereas in 
resistant cells the levels of HSP90 are retained despite the presence of ganetespib. Upon 
17-AAG treatment, the levels of client proteins were reduced in HCT116, SW1463 and HT29 
cells. In SW480 cells, which display a slightly increased 17-AAG-tolerance, the client protein 
levels were retained. This result confirms that the two HSP90 inhibitors have different effects 





Figure 3.10: Ganetespib and 17-AAG induce different effects on levels of HSP90 clients in 
CRC cell lines.  
Ganetespib-sensitive (SW480, HCT116) and ganetespib-resistant (SW1463, HT29) cells were 
treated with 500 nM ganetespib (a) and 1,000 nM 17-AAG (b) for 48 h. Subsequently total 
protein lysates were prepared and an immunoblot analysis of the HSP90 clients AKT and 
Wee1 was performed. GAPDH serves as a loading control. 
 
 Susceptibility of Ganetespib-Resistant and -Sensitive Cell Lines to Second 3.6
Generation HSP90 Inhibitors 
Next, we addressed the question, whether ganetespib-sensitive and -resistant cells 
show similar susceptibility to other second generation inhibitors. Therefore, SW480, 
HCT116, CaCo2, SW1463, and HT29 cells were treated with different concentrations of 
second generation inhibitors. IC50 values for PU-H71, SNX-2112, AUY922, and ganetespib 
were assessed based on confluence measurements with the Celigo
®
 system (Figure 3.11). We 
found that all cell lines are equally susceptible to the treatment with PU-H71, an inhibitor 
based on a purine scaffold, or SNX-2112, an inhibitor that represents a class of its own. 
Contrastingly, the ganetespib-resistant cell lines SW1463 and HT29 exhibit increased 
tolerance to the resorcinolic HSP90 inhibitors AUY922. These data imply that a similar 




Taken together our analysis suggests that this mechanism is largely due to UGT1A-mediated 
glucuronidation of resorcinolic compounds. 
 
   
Figure 3.11: Susceptibility of cell lines to different classes of second generation inhibitors.  
Determination of the IC50 values was performed with the Celigo
®
 system as described in 
chapter 2.2.1.6, for PU-H71, SNX-2112, AUY922 and ganetespib. The error bars represent 





4.   Discussion 
 
 UGT1A Renders CRC Cells Resistant to Ganetespib  4.1
The second generation HSP90 inhibitor ganetespib is a promising drug for the 
treatment of several cancer types.
[40]
 However, the susceptibility to this drug varies 
significantly between cell lines derived from colorectal cancer (CRC) and the aim of this 
study was to elucidate the determinants that govern the cells response to treatment with this 
HSP90 inhibitor. We found that ganetespib susceptibility is dependent on the expression of 
the UDP-glucuronosyl-transferase 1A (UGT1A). This metabolizing enzyme is able to 
deactivate ganetespib inside the tumor cells by glucuronidation. Therefore, high expression 
levels of UGT1A renders cells resistant to the treatment with ganetespib (Figure 3.1).  
The protecting effect that UGT1A has on CRC cells during ganetespib treatment was 
observed when screening cell proliferation and HSP90 client protein levels (see chapter 3.1 
and 3.2). Our results show that the levels of HSP90 client proteins are no degraded in the 
presence of UGT1A, despite the treatment with ganetespib. This confirms the direct causal 
connection of the ganetespib resistance to an abrogation of the HSP90 inhibitory function of 
the drug. Thus, the resistant cell lines are not better equipped to cope with effects of HSP90 
inhibition, but are simply able to deactivate ganetespib in a fast and efficient manner before 
the drug exerts its inhibitory effect on HSP90. Once the cells are deprived of UGT1A, and 
therefore of the ability to glucuronate ganetespib, their high tolerance to the drug is lost 
(Figure 3.2).  
In cooperation with Synta Pharmaceuticals
®
, the manufacturer of ganetespib, a 
bioanalytic study was performed. This analysis confirms the direct glucuronidation of 
ganetespib by UGT1A via mass-spectrometric detection of the glucuronides in cell lysates 
and media (Figure 3.7). 
The deactivation of the lipophilic xenobiotic ganetespib by UGT1A does not 
represent a novelty in itself as this process is a known hepatic detoxification system for such 
compounds and several chemotherapeutics are known substrates of UGT1A (see chapter 4.2). 
However, our results show that ganetespib is metabolized inside of the cancer cells at a rate 
that is sufficient to render the cells resistant to the treatment. This is a considerable turnabout 





 UGT1A and the Resistance to Other Anti-Cancer Drugs 4.2
Our finding that ganetespib is deactivated by UGT1A in CRC has very important 
implications for the application of this HSP90 inhibitor in the treatment of cancer. However, 
UGT1A represents one of the most important drug metabolizing enzymes and has a broad 




In a previous study, gene expression profiles of xenografts derived from nine different 
tumor types were correlated with their intrinsic drug resistance to seven different DNA-
targeting anticancer drugs.
[99]
 This study identified UGT1A expression as one of 32 genetic 
markers that influence the susceptibility to anti-cancer drugs in general. Therefore, and based 
on our own findings, we suggest that a regular screen for UGT1A expression in tumor 
biopsies prior to chemotherapy will prove helpful for pre-evaluation of chemotherapeutic 
treatment in general (see also chapter 4.9). 
Among the several anti-cancer drugs subject to glucuronidation by UGT1A are the 
topoisomerase inhibitors irinotecan and etoposide, as well as the hormone receptor binding 
compounds flutamine and tamoxifen.
[100,101]
  
For irinotecan, a standard-of-care drug in second line treatment of advanced CRC, it 
has been shown that high expression levels of UGT1A can lead to resistance to treatment 
with this drug.
[100]
 SN-38, the active form of this topoisomerase inhibitor, which is formed by 
carboxylesterases, is subject to glucuronidation by UGT1A1.
[102]
 Also, the possibility has 
been proposed that the development of a drug-induced resistance after prolonged treatment of 
lung cancer cells with irinotecan is due to the upregulation of UGT1A.
[103]
 We suggest that a 
similar development of resistance might also be observed for ganetespib during treatment of 
cancers with the drug. 
Just as increased UGT1A expression can render CRC cells resistant to irinotecan 
treatment, conversely the lack of hepatic UGT1A activity can lead to severe irinotecan 
toxicity in patients with reduced UGT1A activity. For instance, gene polymorphisms in the 
UGT1A locus which lead to reduced activity of the UGT1A1 isoform expressed in the liver 
result in a high risk of hematologic toxicity during irinotecan treatment.
[104]
 Therefore, 
UGT1A1 can be used as a drug related-biomarker for the treatment with irinotecan and the 
UGT1A locus of patients could be genotyped before treatment. When UGT1A 
polymorphisms are observed that obstruct the glucuronidation of irinotecan, the drug dose 
should be reduced.
[79,104]




patients lack hepatic UGT1A activity. Therefore, once the UGT1A isoforms responsible for 
ganetespib glucuronidation are identified, a similar genotyping step prior to drug 
administration could be useful for ganetespib treatment to ensure the patient´s safety (also see 
chapter 4.9).  
UGT1A does not only have an influence on the metabolism of anti-cancer drugs but it 
is also responsible for the glucuronidation of carcinogens.
[100]
 Therefore, one has to keep in 
mind that a loss or impediment of UGT1A activity by mutations or through decreased 
expression could influence the metabolism of carcinogens as well as chemotherapeutic 
agents. Following, it will affect the efficacy of both. The overall effect of UGT1A 
deregulation in cancer might therefore be a complex and multidimensional one.
[101]
 Thus, 
assumptions based on UGT1A expression levels have to be drawn carefully. 
 
 Implications for the Different Classes of HSP90 Inhibitors 4.3
As UGT1A is known to be involved in the resistance to many drugs, we hypothesized 
that it might be involved in the metabolism of other classes of HSP90 inhibitors as well. 
Therefore, we compared the susceptibility of CRC cell lines to HSP90 inhibitors from other 
classes. Our results indicate that not all inhibitors exhibit varying susceptibilities in the panel 
of CRC cell lines.  
The high expression of UGT1A in SW1463 and HT29 cells correlates to a tolerance 
to the HSP90 inhibitors ganetespib and AUY922 (see chapter 3.4 and 3.6). This might be 
explained by the fact that both drugs contain a resorcinol moiety as a possible 
glucuronidation site (also see chapter 4.7). For AUY922, the turnover to a glucuronide has 
already been proposed as the main route of metabolism.
[105]
 Our study proves this directly by 
detection of the metabolites via mass spectrometry (see chapter 3.4). Meanwhile, increased 
UGT1A expression does not have any effect on the susceptibility of the CRC cells to HSP90 
inhibitors that are not based on resorcinol, i.e. 17-AAG, PU-H71 or SNX-2112 (see Figure 
3.9 and Figure 3.11).  
The only cell line which exhibits a high tolerance to one of the other drugs is the 
CaCo2 cell line, which is able to withstand high concentrations of 17-AAG (see Figure 3.9). 
The reason for this low susceptibility of CaCo2 cells to 17-AAG is the lack of NQO1 activity 
due to a mutation in this gene, which leads to the proteasomal degradation of the protein. As 







The HSP90 inhibitors PU-H71, which based on a purine scaffold, and SNX-2112, that 
represents a structural class of inhibitors of its own, are active in all CRC cell lines tested 
here. Therefore, these two drugs do not appear to be subject to glucuronidation by UGT1A as 
they do not contain a resorcinol and are not dependent on the activation by NQO1 as they do 
not contain a quinone moiety.  
In conclusion, UGT1A activity determines the resistance of CRC cells to the HSP90 
inhibitors that contain a resorcinol, but does not influence the efficacy of inhibitors from 
other classes. 
 
 Role of UGT1A Glucuronidation in Other Cancer Types 4.4
Interestingly, very recently a similar resistance to resorcinolic HSP90 inhibitors by 
UGT1A-catalyzed glucuronidation has been described in bladder cancer cell lines.
[107]
 This 
study by Acquaviva and coworkers confirms our findings and shows that the concept of 
resistance to resorcinolic HSP90 inhibitors by glucuronidation can be transferred to other 
UGT1A expressing cancer types. 
The basal UGT1A expression levels in the parental tissue seem to be the determining 
factor for the capacity of a cancer to exhibit resistance to resorcinolic HSP90 inhibitors. 
Therefore, our results cannot be transferred to all cancer types. Analysis of the tissue specific 
mRNA expression levels with the human protein atlas reveals that UGT1A is expressed in 
liver, kidney, duodenum, urinary bladder, small intestine, esophagus, colon, stomach, and 
skin (in the order of decreasing amounts of UGT1A mRNA).
[108]
 Epithelial tumors arising 
from these tissues might exhibit resistance to ganetespib or AUY922 by increased expression 




In follow-up experiments to the work presented here, cancer cell lines derived from 
the tissues mentioned above should be analyzed for their UGT1A expression and tested for 
their capability to withstand ganetespib or AUY922 treatment. According to the human 
protein atlas, some cancer cell lines derived from skin (HaCaT) and the urinary bladder 
(RT-4) express high levels of different UGT1A isoforms.
[108]
 The RT-4 cell line has already 
been described to show ganetespib resistance.
[107]
 These two, as well as other UGT1A 






 Other Factors that Might Influence the Efficacy of Glucuronidation by UGT1A 4.5
The list of genes that was retrieved from correlation of microarray data of the CRC 
cell lines to their ganetespib susceptibility (ganetespib-susceptibility genes) was the initial 
indication for the linkage of UGT1A to ganetespib resistance. The three different UGT1A 
probes that were included in the list among the top hits target all UGT1A isoforms (see 
chapter 6.1). We further investigated UGT1A as it represented the most interesting candidate 
due to its known function in drug metabolism (chapter 1.6.3). Apart from UGT1A, the list 
might also contain other candidate genes whose expression levels might correlate with the 
potential of the cell lines to cope with ganetespib treatment. We did not further investigate 
any of these other candidate genes. 
HSP90 client proteins could play a crucial role in determining the ganetespib 
susceptibility. For instance, some essential clients might be expressed at lower levels in 
ganetespib sensitive cells compared to resistant cell lines, and as a consequence treatment 
with the HSP90 inhibitor would render the sensitive cells completely devoid of these 
proteins. This could explain the difference in ganetespib susceptibility of the two groups of 
cell lines. However, none of the known HSP90 clients were found in the list of top hits of the 
statistical analysis. Also, as described in chapter 4.1 the client protein levels are maintained in 
resistant cell lines despite HSP90 inhibitor treatment (see Figure 3.6). Therefore, at least in 
the current study, our results suggest that it is not the degradation of particular client proteins 
that determines the susceptibility of the cells to ganetespib treatment. 
 
4.5.1 Transcriptional Regulation 
Like all reactions from the drug metabolism, the glucuronidation of xenobiotics is a 
process that is accurately regulated in dependence of tissue, environmental influences, and 
substrate levels.
[80]
 However, the reasons for the constitutively high expression levels of 
UGT1A in the ganetespib-resistant CRC cell lines remain elusive. Interestingly, the gene list 
from the microarray correlation contains some transcriptional activators which correlate 
positively with ganetespib resistance and some transcriptional repressors which correlate 
negatively with ganetespib resistance. These include the helicase-like transcription factor 
(HLTF), the transcription elongation factor A protein-like 4 (TCEAL4), hairy and enhancer 
of split 2 (HES2), and CCR4-NOT transcription complex subunit 2 (CNOT2). It is possible 
that these transcription factors are responsible for the high differences in UGT1A expression 




these transcriptional regulators and chromatin immunoprecipitation (ChIP) experiments could 
be performed to investigate their binding to the promoter region of the UGT1A gene locus. If 
such binding sites are found, the effect of inhibition or depletion of this transcription factor 
on the mRNA levels of UGT1A could then be investigated. 
Apart from these general transcription regulators there are some xenobiotic-
responsive transcription factors which have been described as regulating the expression of 
UGT1A isoforms. Among the most important of these receptors are the aryl hydrocarbon 
receptor (AhR), the constitutive androstane receptor (CAR) and the pregnane X receptor 
(PXR).
[110]
 Each receptor responds to different xenobiotic compounds and coordinates the 
detoxification of many lipophilic xenobiotics by inducing different enzymes from phase I and 
II of drug metabolism, including varying isoforms of UGT1A.
[110,111]
 They are predominantly 
found in the liver and the intestine and are also expressed in tumors derived from these 
tissues.
[112]
 PXR has been described as inducing expression of UGT1A isoforms 1, 9, and 10 
and as being involved in drug resistance mechanisms.
[112,113]
 For instance, the upregulation of 
UGT1A1 by PXR overexpression has been previously shown to render colorectal cancer cells 
resistant to treatment with irinotecan.
[113]
 Furthermore, a xenobiotic response element and a 
phenobarbital-responsive element, which can be bound by the AhR and CAR respectively, 
have been found in the promoter region of UGT1A1.
[114,115]
 
None of the xenobiotic-responsive transcription factors were identified in the list of 
genes potentially relevant for ganetespib-resistance. However, the aryl-hydrocarbon receptor 
repressor (AHRR) was found among the gene hits (see chapter 6.1) and correlated negatively 
with ganetespib resistance. Therefore, this repressor element, which is able to suppress the 
activity of AhR, might be responsible for the low activity of this metabolism-activating factor 
in ganetespib sensitive cells.
[116]
 A knockdown of this repressor in the sensitive cells could be 
performed to test this hypothesis. 
As the xenobiotic-responsive transcription factors were not included in the list of 
ganetespib-susceptibility genes, the high constitutive expression levels of UGT1A in 
SW1463 and HT29 cells seems to be independent of the activation by these transcription 
factors. However, the microarray data were generated from untreated cells and do not include 
the effects of drug treatment on the mRNA levels. Therefore, we cannot rule out the 
induction of UGT1A by xenobiotic-responsive transcription factors after treatment with 
lipophilic drugs such as ganetespib and they may still play an important role in enhancing 
ganetespib glucuronidation in resistant CRC cell lines. A vast variety of xenobiotics, i.e. 
drugs, but also food substances, have been found to bind PXR.
[113]




xenobiotic-recognizing receptors by co-administered drugs or food substances that would 
lead to increased UGT1A expression must be taken into account as a possible source of drug-




After treating the cells with ganetespib we did not observe higher protein levels of 
UGT1A (Figure 3.10), hence ganetespib does not seem to influence the levels of UGT1A by 
binding to receptors that induce its expression. Nevertheless, the cancerous glucuronidation 
potential might increase after prolonged treatment with one of the resorcinolic HSP90 




4.5.2 Factors Regulating the Activity of UGT1A 
Recently it has been found that the sonic hedgehog transcription factor glioma-
associated protein 1 (Gli1) is able to influence the protein stability of UGT1A. The UGT1A-
mediated Ara-C and ribavirin resistance by glucuronidation of these drugs is dependent on 
Gli1 activity in cell lines derived from head and neck carcinoma.
[117]
 However, Gli1 has not 
been found in the list of genes that correlate with ganetespib resistance. Therefore, UGT1A 
activity in SW1463 and HT29 cells does not seem to be dependent on the stabilizing effect 
that Gli1 has on UGT1A. 
Also, UGT2B7 and UGT1A9 have been shown to interact with other enzymes from 
the UGT1A family by forming heterodimers, thereby affecting their kinetics.
[118,119]
 UGT2B7 
was not listed among the genes that correlate with ganetespib resistance and is therefore 
probably not influencing the high activity of UGT1A in SW1463 and HT29 cells. The 
activation of UGT1A enzymes by UGT1A9 might play a role in the ganetespib resistant cells, 
however the exact levels of individual UGT1A isoforms are not detectable by qPCR analysis 
(see chapter 4.6).  
Listed among the ganetespib-susceptibility genes are several kinases and 
acyltransferases. Their potential function in stabilizing or regulating the function of UGT1A 
could be analyzed further to check if they have a significant influence on the glucuronidation 
of ganetespib. It would be very interesting to study this issue in future experiments as 
potentially essential UGT1A stabilizing or activating factors could be targeted by inhibitors 





4.5.3 Potential Influence of Co-Substrate Supply 
Before UGT1A-catalyzed glucuronidation can occur the co-substrate UDP-glucuronic 
acid has to be available in amounts sufficient for the conjugation of all xenobiotic molecules. 
UDP-glucuronic acid is synthesized by the oxidation of UDP-glucose by UDP-glucose 6-
dehydrogenase (UGDH).
[120]
 As UGDH is not included in the list of statistically relevant hits 
from the microarray analysis, the glucuronidation step executed by UGT1A seems to be the 
step determining the success of ganetespib deactivation. Presumably, UGDH, and therefore 
also the co-substrate UDP-glucuronic acid, are present in sufficient amounts in the resistant 
cell lines to facilitate the glucuronidation of all ganetespib molecules. Thus, UGDH-catalyzed 
oxidation of UDP-glucose is not the rate limiting step of the glucuronidation process. 
 
4.5.4 Potential Influence of Metabolite Transport 
UGT1A is located to the luminal side of the endoplasmic reticulum, and the newly 
generated glucuronides have to be transported past the membrane enclosing this cellular 
organelle. There is evidence for an active transport across this membrane for several 
glucuronides, but the specific transporters have not yet been identified.
[121,122,123]
 
The glucuronides that have been transported into the cytoplasm need to be further 
transported outside of the cell and it has been proposed that glucuronidation has to be 
accompanied by shuttling via a glucuronide transporter for the manifestation of a de novo 
resistance.
[124]
 Several transporters from the ATP-binding cassette transporter sub-family C, 
the multidrug resistance-associated proteins, have been shown to be involved in the excretion 
of glucuronides from the interior of the cell.
[124,125]
 The xenobiotic glucuronides that are 
excreted from the cells are then transported further, e.g. in the bile, and finally excreted via 
urine or feces.  
The appearance of one of the multidrug resistance-associated proteins in the list of 
ganetespib-susceptibility genes would imply that the transport process is highly relevant for 
the glucuronidation efficacy. However, the list does not include any transmembrane 
transporters that could facilitate the excretion of glucuronides from the endoplasmic 
reticulum or the cytoplasm of the cell. Therefore, the resistance-relevant step seems to be the 
deactivation by UGT1A-catalyzed glucuronidation regardless of the rate or the efficiency of 





 UGT1A Isoforms in Ganetespib Resistance 4.6
Due to the high similarity of the UGT1A genes in the two isozyme clusters (isoforms 
3-5 and isoforms 7-10; chapter 1.6.3), it is virtually impossible to design primers that are 
specific for individual isoforms within each cluster. Therefore, the isoforms were amplified in 
qPCR using primers targeting the sequences of all isozymes of one cluster (Figure 3.4, see 
chapter 2.1.7.1 for primer sequences). The cluster of the isoforms 7-10 was highly expressed 
in the most ganetespib-resistant cell line, HT29. Therefore, the isoform 10 was chosen for 
overexpression in the ganetespib-sensitive cell lines SW480 and HCT116 in order to establish 
higher ganetespib tolerance in these cell lines (see Figure 3.5 and Figure 3.6).  
Based on the finding that the isoform 10 is able to glucuronate ganetespib and 
establish tolerance to the drug in CRC cell lines, it would be of interest to check which other 
isoforms from the clusters 3-5 and 7-10 are also able to metabolize resorcinolic HSP90 
inhibitors. These may then be used as biomarkers for ganetespib treatment (see chapter 4.9). 
The isoforms 7, 8, and 9 are 96 - 97% identical to UGT1A10, compared to ~75% for the 
other five isoforms. Therefore it is likely that isoforms 7, 8 and 9 glucuronidate the same 
targets as isoform 10 and are also capable of conjugating ganetespib.  
UGT1A is very unequally expressed between the CRC cell lines. It is therefore also of 
interest to find the reasons for this significant difference in expression, as this could give rise 
to strategies for pretreatment screening of ganetespib susceptibility or for suppressing 
UGT1A expression to prevent the deactivation of the drug. Continuous activation or 
overexpression of transcription factors that induce the expression of particular UGT1A 
isoforms in the ganetespib-resistant CRC cells might be responsible for the observed high 
levels of the enzyme. Inhibition of these transcription factors could lead to a downregulation 
of UGT1A expression. 
Mutations in the promoter sites of the UGT1A genes could theoretically explain the 
strikingly low levels of UGT1A expression in the sensitive cell lines, but there is currently no 
empirical evidence for such a scenario.  
Single nucleotide polymorphisms in the common exons 2-5 of the UGT1A gene 
cluster which encode the active site of the enzyme have previously been shown to influence 
the glucuronidation capacity of individuals.
[126]
 Mutations in these exons could explain the 
lack of ganetespib resistance in SW403 cells, which exhibit relatively high UGT1A 





 Strategies to Circumvent Ganetespib Resistance by Glucuronidation 4.7
One strategy to circumvent the deactivation of the resorcinolic HSP90 inhibitors by 
glucuronidation would be to alter the chemical structure of the drugs to prevent the transfer of 
the glucuronic acid onto hydrophilic side chains. 
Dissection of the chemical structures of the HSP90 inhibitors ganetespib and 
AUY922 reveals that they share the resorcinol moiety and the adjacent heterocycle (see 
Figure 4.1). In ganetespib this heterocycle is a triazolone, in AUY922 it is an isoxazole. The 
resorcinol and the adjacent heterocycle form the core of interaction between the HSP90 
inhibitors and the ATP binding pocket of HSP90.
[40,105]
 Our data show that only these two 
drugs are subject to glucuronidation by UGT1A, in contrast to HSP90 inhibitors from other 
classes. Thus, it is likely that the glucuronosyl-group gets attached to a site that is only 
present in these two compounds.  
 
Figure 4.1: Chemical structures of ganetespib and AUY922 with HSP90 interacting sites.  
Ganetespib, AUY922 with resorcinol (red) and the adjacent heterocycle (green). 
 
Other resorcinol containing compounds have previously been analyzed for their 
metabolism by glucuronidation. For instance the mycotoxine zearalenone as well as 
resorcinol itself are subject to glucuronidation at one of the sterically unhindered resorcinolic 
hydroxyl groups.
[127,128]
 Therefore, it is conceivable that the glucuronate gets attached to the 
hydroxyl groups of the resorcinol. 
A chemical modification of the resorcinol or the adjacent nucleophilic heterocycle 
might therefore hamper the glucuronidation and prevent the deactivation of the drugs. On the 
other hand, these moieties constitute the site of drug-target interaction and form hydrogen-
bonds with the amino acid side chains in the ATP-binding pocket of HSP90. Thus a 
substitution or modification of these chemical structures would probably compromise the 
efficacy of the drugs. Therefore, the potential for glucuronidation by UGT1A is an attribute 




Another strategy to circumvent the deactivation of the resorcinolic HSP90 inhibitors 
by glucuronidation would be the inhibition of UGT1A. However, such an approach would 
only be possible once the responsible UGT1A isoforms are known and isoform-specific 
inhibitors become available. The inhibition of all isoforms would have deleterious 
consequences, as for instance the glucuronidation of bilirubin, which is catalyzed by 
UGT1A1, would also be affected. When bilirubin is not metabolized efficiently, it 
accumulates in the blood and at high concentrations it passes the blood-brain barrier in to the 
brain, where it can cause fatal necrosis of neurons.
[88]
 Only the targeted inhibition of 
particular isoforms which are responsible for glucuronidation of resorcinolic drugs could 
ensure a safe co-treatment. 
Also, once the transcription factors that mediate the upregulation of UGT1A 
expression in cancer cells are identified, these could also be targeted by inhibitors to prevent 
the excessive expression of UGT1A and to thereby hamper the glucuronidation.  
 
 Implications for the Clinical Use of Resorcinolic HSP90 Inhibitors 4.8
The findings described in this work have several very important implications for the 
clinical application of resorcinolic HSP90 inhibitors.  
First of all, it is of pivotal importance to identify the isoforms that are responsible for 
the glucuronidation of these resorcinolic HSP90 inhibitors (see chapter 4.6). Severe drug-
drug interactions may be possible due to the mutual dependence of two drugs on the same 
UGT1A isoform for glucuronidation. The two compounds would compete for the turnover by 
UGT1A and could therefore exceed the glucuronidation capacity of the responsible UGT1A 
isoforms, resulting in drug accumulation. Alternatively, strong adverse effects may be 
observed when the relevant UGT1A isoforms are inhibited by a co-administered drug.
[80]
 By 
understanding the exact metabolism of these inhibitors by UGT1A isoforms these drug-drug 
interactions can be avoided. However, these drug-drug interactions are not very frequent for 
substrates of phase II reactions of the drug metabolism and the UGT1A enzymes are fairly 
promiscuous in their substrate specificity.
[129]
 Several UGT1A isoforms might be able to 
metabolize the components of the drug mixture, which reduces the probability of drug-drug 
interactions due to enzyme metabolism dependence.
[129]
 Meanwhile, co-administered drugs or 
food substances could also lead to the increased expression of UGT1A through induction of 




these organs (see chapter 4.5.1). The consequence would be reduced activity of the HSP90 
inhibitors.  
These potential drug-drug interactions have to be considered, especially as the HSP90 
inhibitors are presumably mainly used in combinational treatment. 
To evaluate the feasibility of ganetespib for clinical applications it is of crucial 
importance to further elucidate the processes that govern the response to ganetespib treatment 
in vivo. Therefore, xenograft models and clinical studies are essential. 
 
4.8.1 Mouse Models for in vivo Studies of Resorcinolic Hsp90 Inhibitors 
To analyze whether the difference in cancer growth can be observed in vivo, resistant 
and sensitive CRC cells could be used in parallel in a xenograft model under treatment with a 
resorcinolic HSP90 inhibitor. 
In previous xenograft experiments, the ganetespib-sensitive cell line HCT116 was 
injected in immunodeficient SCID mice to study the effect of ganetespib as a single agent for 
cancer treatment.
[130]
 He and coworkers did show that the use of ganetespib alone has only a 
relatively modest effect on the tumor growth rate (decrease of approx. 50%) in xenografts. 
However, treatment of the xenografts with the HSP90 inhibitor increases the chemo- and 
radio sensitivity of the cancer cells. Therefore, combinational treatment of ganetespib with 
chemotherapeutics resulted in increased response to conventional chemotherapy. This need 
for a combinational treatment in xenografts would render the comparison of ganetespib 
efficacy in the different cancer lines very complicated, as multiple factors would affect the 
outcome of the applied drug combination.  
Moreover, xenograft experiments with ganetespib are further complicated by the fact 
that ganetespib has to be administered by intravenous injections in mice models, which 
makes the application in nude mice very finicky, as their tail veins are prone to collapse.
[130]
 
The complicated drug application and the fact that direct deduction of differences in 
ganetespib susceptibility might not be possible when the drug is used in combinational 
treatment, have to be considered before running xenograft experiments.  
Aside from xenograft experiments, a CRC-tumor mouse model could serve as a good 
substitute for studies in human. As the mouse UGT1A genes are arranged in a similar manner 
to the human gene locus and are highly conserved between the two species, insights deduced 
from studies in mouse models can be transferred to humans.
[131]
 For instance, the mouse 




study the response of CRC to resorcinolic HSP90 inhibitor treatment.
[132]
 The developing 
tumors would be challenged with ganetespib or AUY922 and the growth rates of the 
individual cancers would be analyzed for a correlation to the in vivo expression levels of 
UGT1A. 
 
4.8.2 Clinical Studies 
Of course clinical trials represent the most informative approach for the elucidation of 
medical benefit. On the other hand, they also carry considerable risk for the participants and 
their safety has to be ensured. Therefore, thorough preclinical trials should precede the 
clinical application. For ganetespib and AUY922 these precautions have already been taken 
and the drugs are currently studied intensively in clinical trials.  
The findings presented in this study entail some very important implications for the 
clinical use of ganetespib. However, a prerequisite for the transfer of the findings to the 
clinical application is a comparable spectrum of expression levels of UGT1A in primary CRC 
tumors compared to the CRC cell lines. For the development of a resistance to ganetespib 
similar to the in vitro resistance observed in CRC cell lines, the primary tumors must express 
comparable levels of UGT1A.  
It has been reported that UGT1A levels are reduced in colon cancer as compared to 
normal colonic mucosa, albeit not in all cancer samples.
[133]
 On the other hand, it has been 
previously described that biopsies from CRC patients the expression of UGT1A is often 
higher than in HT29 cells.
[100]
 In previous studies, microarray hybridization datasets were 
obtained from 217 colorectal carcinomas.
[134,135]
 When comparing the UGT1A expression 
levels in the panel of eleven colorectal cancer cell lines with those of primary tumor samples, 
it becomes apparent that the range of expression of the tumors resembles the range of 
expression in the CRC cell lines (Figure 4.2). Therefore the resistance to resorcinol-based 
HSP90 inhibitors in colorectal cancer patients might become a real obstacle for successful 
treatment. 
A clinical trial with resorcinolic HSP90 inhibitors as single agents in CRC patients 
would have high relevance for the validation of the findings presented in this work. An 
analysis of the UGT1A expression levels of individual cancer samples could give insight in a 
potential correlation between UGT1A expression and a response to ganetespib treatment i.e. a 
change in tumor growth. Also, in long term studies the possibility of drug induced resistance 





Figure 4.2: Overlay of distributions of UGT1A expression levels in primary tumor samples 
and in vitro CRC cell lines (graphic kindly provided by Frank Kramer) 
The mean hybridization intensities from three UGT1A microarray probes were normalized 
according to their deviation from the overall mean intensity of all tumors (log2 scale). The 
UGT1A expression levels of the CRC cell line panel is overlaid on the distribution of the 217 
primary tumor samples. 
 
 UGT1A as a Drug-Related Biomarker for Ganetespib Treatment 4.9
The fact that the resorcinolic HSP90 inhibitors ganetespib and AUY922 are subject to 
UGT1A-catalyzed glucuronidation is very important for the stratification of treatment in 
cancer patients. The UGT1A-catalyzed deactivation makes the treatment of cancers from the 
small intestine and other tissues with high metabolic potential very complicated. Until 
measures for a reliable screening of UGT1A expression are available, the administration of 
these drugs should only be considered as a last treatment option when other measures have 
failed. Until the actual benefit and the possible side-effects can be predicted with reasonable 
certainty, the application should be limited to specific tumors that were previously shown to 
be highly susceptible to HSP90 inhibition, like anaplastic lymphoma kinase (ALK)-driven 
non-small cell lung cancer and Her2-overexpressing breast cancers.
[49,50]
 
However, once the screening methods for UGT1A activity in the tumor sites become 




tumors with low levels of UGT1A and only patients with sufficient UGT1A activity in the 
liver should be treated with resorcinolic HSP90 inhibitors to ensure drug efficiency and to 
prevent toxicity.  
There are two general routes to screen for the UGT1A levels in the tumors. Either the 
protein levels can be detected through antibody-binding or the mRNA levels can be 
determined by molecular biological methods.  
By determining the protein levels through histological methods the tumor levels of 
UGT1A can be detected in clear distinction from the surrounding tissue. However, it would 
be virtually impossible to distinguish between the different isoforms of UGT1A, as different, 
isoform-specific antibodies would have to be used and many tissue sections would have to be 
stained in parallel. Therefore, it would be preferable to establish a screening for UGT1A 
mRNA expression levels from primary tumor samples in the clinics, ideally in a highly 
standardized fashion that guarantees the comparability of expression levels between patients.  
 
4.9.1 Clinical Assessment of UGT1A mRNA Levels  
Methods for the detection of the whole transcriptome, like microarray analysis or 
RNA-seq, are very time-consuming and costly and are best suited to identify candidate 
biomarkers or to elucidate the impact of whole gene set amplification or pathway activation 
on observed phenotypes.
[136,137]
 For the every-day use in high throughput screenings of the 
expression of a known single target gene (e.g. UGT1A) the qPCR is the only efficient and 
economic method.
[138]
 The real-time measurement of the amplification process allows the 
precise quantification of the amount of starting material, the target mRNA. It is facilitated by 
real-time quantification of fluorescence, either by using a fluorescent dye that intercalates 





are fluorescence-labeled DNA fragments that bind specifically to the target sequence and 
only give a signal when the gene sequence is subject to an amplification reaction with taq-
polymerase.
[139]
 The use of TaqMan
®
 probes is costly, but allows the analysis of gene 
expression in a customizable and standardized fashion that is comparable across samples and 
laboratories.
[140,141]
 Also, as the TaqMan
®
 probes span a smaller region of DNA compared to 
primers for standard qPCR, it might be possible to target individual UGT1A isoforms for 
quantification, something that is not feasible with standard qPCR (see chapter 1.6.3 and 4.6). 
Depending on the probe design, the TaqMan
®
 method can also be applied to screen for 
genetic polymorphisms.
[142]




isoforms, but can also provide information on functional impairment of the isoforms by 
mutations. 
 
4.9.2 Standardization of the mRNA Evaluation Process 
The highly standardized evaluation of mRNA expression is essential for the 
assessment of mRNA levels that are comparable between samples and across laboratories.  
Different ways of sample extraction from primary tumor sites might yield samples 
with different cellular composition and can result in different gene expression profiles.
[143]
 
Therefore, standardized obtainment and preservation of mRNA samples from clinical 
biopsies is the first crucial step in a comparable expression level analysis. The primary tumor 




Absolute gene quantification requires a quantitative calibrator, e.g. a dilution series of 
the target sequence isolated from a conventional PCR. Reference genes, which are constantly 
expressed in the analyzed tissue at invariable levels, could be co-amplified to serve as 
internal standards. 
Clinical trials would be necessary to prove the suitability of UGT1A mRNA 
expression determination as a drug-related biomarker to predict ganetespib response. These 
trials should be designed such that in the phases I and II, the accuracy, reliability, and 
reproducibility of the technology can be proven in application to clinical specimen collected 
in different facilities. The subsequent phase III should evaluate the improvement of clinical 
outcome under use of the established biomarker in a large number of cases.
[145]
  
Additionally to the screening of tumor site expression levels of UGT1A to predict the 
case specific drug efficacy, the patient´s somatic UGT1A genotype should be determined or 
the systematic activity of the hepatic UGT1A isoforms should be tested, to prevent adverse 
effects in the patients during treatment with resorcinolic HSP90 inhibitors. When an activity-
hampering polymorphism or a decreased UGT1A activity is found, the drug dose should be 
adjusted accordingly.
[79]
 There are many polymorphisms in various metabolic enzymes 
known to cause severe side effects. However, screening for these mutations is rare and almost 
exclusively done for patients that exhibit unexplained adverse effects or lack of response.
[79]
 
This ‘trial-and-error’ approach for chemotherapeutic drug dose adjustments is risky and can 






In the case of the resorcinolic HSP90 inhibitors the clinical application in CRC and 
other cancers with potential to express UGT1A will have to be preceded by intensive studies 
on the drug’s efficacy and on possible toxicity hazards. 
 
 Concluding Remarks 4.10
In this study we show that the biological activities of ganetespib and AUY922, two 
resorcinolic HSP90 inhibitors, are impaired by UGT1A catalyzed glucuronidation in CRC 
cell lines. The glucuronidation is specific for this class of HSP90 inhibitors and is expected to 
be more prevalent in cancers derived from tissue with a basal expression of UGT1A.  
Some open questions remain to be addressed in the aftermath of this work. For 
instance the influence of transcription factors, kinases or acyltransferases on the expression 
and activity of UGT1A could be investigated further. Also, the UGT1A isoforms responsible 
for the glucuronidation of ganetespib and AUY922 are of major interest for the clinical 
application of these drugs. The knowledge of the responsible isoforms would enable the 
screening of hepatic UGT1A activity to prevent increased toxicity during drug treatment.  
Most importantly, the establishment of a reliable standardized screening of UGT1A 
expression in cancer cells is crucial to select patients who could benefit from treatment with 
these drugs. Thus the absence of UGT1A from tumor cells is expected to predict efficient 
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   Appendix 6.
 Gene List from the Statistical Analysis  6.1
(Gene list is showing all genes of statistical relevance with a p-value of <0.005 and additional 
hits relevant for this work, the UGT1A hits are shown in bold and underlined, other hits 
mentioned in the discussion are shown as underlined italics) 
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